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ABSTRACT  
Introduction: Malnutrition is common in children with end-stage liver disease but recovery 
is expected after transplantation. Early childhood under-nutrition is recognised to 
contribute to adult disease.  There is however, limited information on long-term outcomes 
and nutritional recovery after childhood liver transplantation. 
Aims: The aims of this thesis therefore were to examine several long-term outcomes in 
survivors of childhood liver transplantation, which potentially may have been impacted by 
malnutrition prior to liver transplant. The specific areas examined were: 
Specific Aim 1: Growth and anthropometry;  
Specific Aim 2: Body cell mass (BCM);  
Specific Aim 3: Bone mineral density (BMD); and  
Specific Aim 4: Cognition, behaviour, and academic function.  
Methods: All patients transplanted aged <18 years, who survived >3 years after initial 
transplant, with ongoing review by the Queensland Liver Transplant Service were eligible. 
Since testing was only available in Brisbane, most participants were resident in 
Queensland. 
SA 1:  Patients with ≥2 measurements, of which one was ≥5 years post-transplant, were 
considered. Height, weight, and body mass index data were collected at transplant, 1, 5, 
10, and 15 years post-transplant to assess longitudinal growth and anthropometry. WHO 
reference ranges were used for Z-scores. 
SA 2: Total Body Potassium (TBK) measurements, were obtained pre-transplant, and at 
long-term follow up to examine longitudinal change post-transplant. BCM was calculated 
from TBK and adjusted for height raised to the power p depending on gender 
(BCM/Heightp).  
SA 3:  Cross-sectional assessment of BMD in patients >5 years post-transplant, was 
performed using Dual Energy X-ray Absorptiometry (DXA). Wrist X-ray was performed to 
assess bone age.  
SA 4: Patients surviving >5 years post-transplant, and still attending school were eligible. 
Hearing and comprehensive neuro-psychometric tests were undertaken by participants, 
and sibling controls.  
Results:  
SA 1: Longitudinal height and weight data were available on 98 and 104 patients 
respectively. 58% were Australian, and the rest Japanese. Height recovery continued for 
≥10 years, reaching the 26th centile, although Australian patients did better and attained 
47th centile. Weight recovery was most marked in the first year and continued for 15 years 
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even in the well nourished. Growth impaired and malnourished children had the best 
recovery, but remained shorter and lighter. Gender and age at transplant did not affect 
height or weight recovery. Dichotomous growth recovery between Australian and 
Japanese patients was likely due to post-transplant factors. At 10-15 years post-transplant, 
9% were overweight but none obese.  
SA 2: TBK measurements were performed in 32 patients at median 7.23 (range 3.28-
14.99) years when they were aged 10.12 (range 4.56-20.77) years. This cohort attained 
mean Z-scores for height -0.41, weight -0.26, and BMI 0.04. BCM/Heightp was low pre-
transplant, but further reduced post-transplant (p<0.001) despite normalization of height 
and weight, implying that weight recovery was from fat, not BCM. Growth impairment was 
associated with greater reduction in post-transplant BCM/Heightp (p=0.02). On multivariate 
analyses, only older age at transplant predicted reduced post-transplant BCM/Heightp 
(p=0.02).  
SA 3: 42 patients were assessed at median 10.10 (5.01-25.98) years post-transplant, aged 
14.64 (6.59-38.07) years. BMD normalized with lumbar spine Z-score -0.15±1.07, 44th 
centile, and total body Z-score -0.76±1.14.  Reduced BMD was noted in four patients 
(10%), with ongoing steroid use a significant factor, p=0.049. Age at transplant, time from 
transplant, and reduced BCM did not predict BMD. Overall fracture incidence, including 
post-traumatic was 12%; pathologic fractures only occurred within 18 months of transplant. 
SA 4: 13 children were assessed at median 10.89 (range 5.16-16.37) years post-
transplant, at age 13.08 (6.52-16.99) years. 6 siblings were also tested. All subjects had 
full scale intelligence quotient (IQ) within normal, with mean IQ 97 and 105 for transplanted 
children and siblings respectively. No difficulties were identified in intellect, cognition, 
academic function, memory and learning, although both groups had reduced mathematical 
ability compared to normal. Transplanted patients had difficulties in self-regulation, 
planning, organisation, problem solving, and visual scanning. Four transplant survivors 
(31%), and no siblings, scored in the clinical range for attention deficit hyperactivity 
disorder (ADHD).  Emotional difficulties noted in transplanted patients were also found in 
their siblings.  
Conclusions:  
SA 1: Children can expect height and weight recovery for at least 10-15 years after liver 
transplant. Growth impairment at transplant and post-transplant care significantly impact 
on final height attained.  
SA 2: Weight recovery after childhood liver transplant is likely due to increased fat since 
BCM remains reduced.  
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SA 3: BMD normalises at 10 years post-transplant, but reduced BMD is more likely in 
those still on steroids.   
SA 4: Long-term liver transplant survivors have intact intellect and cognition, but exhibit 
subtle difficulties in executive function and are more likely to have ADHD. 
 
Long-term survivors after childhood liver transplantation can expect excellent medical 
outcomes with normalization of weight, height, BMD, IQ and cognition, but remain at risk of 
ongoing problems including sarcopenic obesity, executive function difficulties and ADHD. 
Nutritional compromise persists in long-term survivors of childhood liver transplantation. 
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MAIN TEXT 
INTRODUCTION 
End-stage liver disease, when the liver starts to fail, is a devastating condition with 
eventual involvement of multiple other organs and systems. Malnutrition is a prominent 
feature in these patients due to a combination of factors including hypermetabolic state, 
inadequate intake, and malabsorption from cholestatic liver disease1. The nature of 
malnutrition in children with end-stage liver disease has been reported to be from a 
combination of reduction in body fat and protein stores, severely depleted body cell mass, 
as well as deficiencies in fat soluble vitamins, iron, zinc, and selenium2. This condition was 
invariably fatal until the advent of liver transplantation, as unlike renal failure, no successful 
means of external artificial liver support is viable in the long-term. 
 The early years of liver transplantation, first performed in 1963 by Thomas Starzl, 
involved development of improved surgical techniques but was limited by rejection3. The 
introduction of cyclosporine as an immunosuppressant greatly improved patient 
outcomes4. Since then, improvements in surgical techniques, immunosuppressive 
treatment, and peri-operative care have resulted in this procedure being considered the 
standard of care for some liver diseases in adults and children5. While end-stage liver 
disease from various causes remains the predominant reason for transplantation, due to 
the success of this procedure it is increasingly performed for metabolic disease and 
malignancy even in the absence of liver failure.  
In Australia, the first liver transplant was performed in 1985 in Queensland, with the 
longest Australian survivor being a small child at the time of transplant. Current reported 
survival after paediatric liver transplantation in North America is 85% at 5 years and 83% 
at 10 years6. Similar results are reported from Australia and New Zealand with overall 
survival rates in children at 84%, 80% and 74% at 5, 10, and 20 years respectively7. 
Children have better survival rates than adults, and those transplanted in recent years do 
better than those transplanted in earlier eras. The actuarial survival after childhood liver 
transplantation in Australia and New Zealand is 71% at 25 years, which is similar to data 
from Pittsburgh, USA of 77% at 20 years8. While the age of adults receiving a primary 
transplant has increased over time from 43.9 years to 54 years (p<0.001), the median age 
of children requiring transplant in Australia and New Zealand remains unchanged at 2.4 
years7. 
Malnutrition and low body weight is recognised to adversely affect survival after liver 
transplantation in both children and adults.  Studies from Brisbane in the early 1990s 
showed that children who died after liver transplant had significantly reduced weight with 
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mean Z-score -2.26 compared to -1.03 for those who survived9. Furthermore, this 
malnutrition was potentially correctable even before transplantation as there was no 
correlation between degree of malnutrition and degree of synthetic dysfunction or 
cholestasis2. In adult patients, there is developing awareness that low body cell mass and 
sarcopenia, i.e. reduced skeletal muscle, may be significant in predicting morbidity and 
mortality after liver transplantation10, 11. Sarcopenic patients were more likely to have 
serious post-operative infections and reduced survival after liver transplantation; and peri-
operative nutritional therapy found to improve their survival11, 12. The recognition of these 
detrimental effects of malnutrition has resulted in increased interest in pre-transplant 
nutritional rehabilitation in adults with revision of protein recommendations in cirrhotic 
patients, encouragement of nocturnal snacking, and studies examining patients for 
sarcopenia before and after liver transplant13. While all patients are encouraged to snack 
or use nutritional supplements to augment their caloric intake, many children end up on 
supplemental tube feeding and a small minority on parenteral nutrition prior to 
transplantation.  
Improving nutrition in a patient with terminal end-stage liver disease however can 
be challenging. Managing the complications of end-stage liver disease such as ascites, 
oedema, variceal bleeding, hypoglycaemia, and coagulopathy, all of which are potentially 
life threatening often take precedence over managing malnutrition. Attempts to improve 
nutrition are also often limited by anorexia, and the patient’s intolerance of interventions 
such as nasogastric tubes, distasteful nutritional supplements, and early satiety from 
ascites and splenomegaly. Additionally, nasogastic tubes may aggravate epistaxis or 
variceal bleeding in a coagulopathic patient. While aggressive nutritional management has 
reduced morbidity and mortality in children and improved liver transplant outcomes, the 
long-term consequences of this aggressive feeding are unknown.  
The assessment of nutritional state in patients with end-stage liver disease is often 
difficult because of oedema, ascites, and diuretic therapy.  While weight and body mass 
index (BMI) measurements are most commonly used because of easy accessibility, they 
are affected by fluid shifts commonly present in liver disease. Subjective global 
assessment and anthropometric measurements are recognised to underestimate the 
degree of malnutrition in cirrhotic patients when compared to body composition 
measurements14. Skin-fold thickness and mid arm circumference are also often performed 
to assess nutrition but are subject to significant intra- and inter-observer variability. Body 
composition assessment is recognised to be more accurate in the evaluation of nutritional 
status than standard anthropometric measurements15. While some studies have used 
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anthropometry and skin fold or arm circumference measurements to report body 
composition, these are indirect inferences rather than true measures of body composition. 
Direct measurement of body composition include techniques such as bioelectrical 
impedance analyses (BIA), dual energy X-ray absorptiometry (DXA) scans, computed 
tomography (CT) scanning, and whole body counting of isotopes15.  
Body composition analysis has become more sophisticated over time. The two-
compartment model of the early years (fat, and fat-free mass) is now superseded by the 
four-compartment model (fat, body water, mineral, and protein) as body density in children 
is recognised to be affected by variation in fluid and mineral content of fat-free mass16. The 
four-compartment model of body composition recognises bone mass, but is also able to 
differentiate lean mass from extracellular fluid shifts. In contrast, the two-compartment 
model is affected by fluid shifts, and will be less accurate when assessing nutrition in 
conditions where this may occur, such as end-stage liver or kidney disease17. Most current 
techniques including BIA, DXA, CT scan still assess body composition as a two-
compartment model although DXA and the newer peripheral quantitative computed 
tomography scan (pQCT) are able to further differentiate fat free mass into lean mass and 
bone mass or density16. The use of DXA and CT scanning however, results in radiation 
exposure albeit low levels; but this is undesirable in children unless essential for patient 
management. Of current techniques available, total body potassium (TBK) measurement 
is considered the “gold standard” for assessing body cell mass (BCM), the metabolically 
active component of fat free mass. It measures intracellular 40K, which is very stable, and 
is not affected by extracellular fluid shifts. BCM measures the metabolically active total 
body protein encompassing skeletal muscle and visceral organs, but excludes water, fat, 
and mineral, so is very useful in accurately assessing nutritional states, even in those with 
liver disease18. Advances in whole body counting technology have also made TBK 
measurements easier as they are now “plug-and-play”, the detectors are now more robust 
with higher resolution, and the software applications have become cheaper19.   
Liver transplantation corrects the liver dysfunction and malabsorption associated 
with end-stage liver disease so recovery from malnutrition post-transplant is expected. In 
children, weight recovers quickly and often reaches normal centiles by 12-18 months post-
transplant9. Mid arm circumference and triceps skin fold measurements also improve in 
the first 1-2 years after liver transplantation but no further improvement was seen up to 5 
years after transplant20, 21. Adults after transplant also demonstrate rapid weight gain, so 
much so that there are concerns about the development of obesity and post-transplant 
steatosis in these survivors22. The nature of recovery from malnutrition in body 
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composition terms after transplant however, is not well defined. There is limited 
information on body composition after liver transplantation. Several studies in adults have 
reported little or no increase in muscle mass up to 24 months after transplant23. Increased 
weight and fat mass post-transplant has also been reported in adults24. Two studies in 
adults, using phase angle to estimate BCM, report persistently reduced BCM compared to 
normal up to 10 years after liver transplantation24, 25. There is no equivalent data in 
children after transplant, and no information on long-term body composition is available. 
This is despite pre-transplant nutrition being recognised to predict long-term outcomes 
such as height growth26, 27.  
Important determinants of recovery from illness and subsequent quality of life (QOL) 
include the natural history of the disease, and the effect of treatment including medication 
or other therapies. While most of the focus immediately after transplantation has been on 
patient survival, graft function, and side effects of medications, malnutrition is also 
important, as it is almost universal in patients with end-stage liver disease. Under-nutrition 
in early childhood and the rate of recovery from this are recognised to increase the 
likelihood of developing hypertension, diabetes, obesity and metabolic syndrome in 
adulthood28, 29. Dietary factors during critical periods of development may also elicit 
epigenetic factors to result in metabolic re-programming resulting in increased 
susceptibility to disease in adulthood30. These factors are therefore likely to affect 
paediatric patients subjected to aggressive nutritional rehabilitation. The long-term effects 
of malnutrition and subsequent recovery from this have not been adequately studied in 
liver transplant survivors.  
Long-term outcomes after transplantation, particularly in children, are of increasing 
relevance with improved survival. Patient and graft survival are important in the first few 
years after transplant, but other factors such growth, QOL, school attendance, and the 
ability to join the work force are of increasing relevance the longer the patient survives. 
The ability of patients to successfully integrate and fully participate within their community 
is arguably the best indicator of success of any mooted therapy. Outcomes of liver 
transplantation may ultimately be judged by the quality of life years restored incorporating 
both survival rate and quality of time survived31.  
One of the early reports on long-term outcomes after liver transplantation described 
increased incidence of diabetes, hypertension, de novo malignancy and fractures in 96 
adults surviving at least 5 years after liver transplantation32. This study also noted that 47% 
their cohort was obese and 27% had hypercholesterolaemia although these were not 
significantly higher than the USA adult population at the time32. Subsequent publications 
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have confirmed increased prevalence of hypertension, diabetes and dyslipidemia, obesity 
and metabolic syndrome, and renal dysfunction after liver transplantation in adults33. 
Whether these complications also occur after liver transplantation in childhood is 
uncertain, as there are few reports of very long-term follow up coincident with when 
survivors start entering adolescence and early adulthood.  
 There are two reports of 10 year medical outcomes after childhood liver 
transplantation, both from North America. Avitzur et al from Canada found increased 
prevalence of chronic renal failure (77%), mild anaemia (59%), and hypertension (25%), 
while diabetes and hyperlipidemia were uncommon in 32 children followed for 10 years 
post-transplant34. This cohort attained median height Z-score -0.65, corresponding to 23rd 
centile, but 14% were growth impaired and remained below 3rd centile for age34. The 
Studies of Pediatric Liver Transplantation (SPLIT) Research Group, comprising most of 
the North American paediatric liver transplant centres, recently reported an audit of 167 
patients who were still alive and in whom data was available 10 years after initial liver 
transplant35. In contrast to the previous study, dyslipidemia was common with 26% having 
hypertriglyceridemia, 20% hypercholesterolemia, and 9% diabetes35. Renal impairment, 
using calculated glomerular filtration rate, was less frequent at 9% although one patient 
required renal transplantation. Growth impairment remained a significant problem, mean 
height Z-score -0.51 for whole cohort, with 23% <10th centile, and 11% <3rd centile35. In 
contrast, weight normalised, mean Z-score -0.06, and 10% were obese with BMI >95th 
centile although this prevalence was similar to the normal population. Psychosocial 
assessment in these patients revealed lower self-reported health related quality of life 
(HRQOL) and 26% had learning disabilities.  
Lower physical HRQOL and health utility compared to normal was also reported in 
85 patients from a single centre study, 20 years after liver transplantation in childhood36.  
Interestingly, 54% of these patients reported medication side effects, with intermittent 
abdominal pain being the most common complaint.  No attempt however was made to 
differentiate between this perceived side effect, and functional gastrointestinal disease or 
irritable bowel syndrome, which has been reported in up to 38% of American children37. 
One patient had a kidney transplant, 24% self reported hypertension and 19% were on 
antihypertensive treatment36. Despite reduced physical HRQOL, this cohort managed to 
achieve high rates of education with 63% attending or completing college and 80% of 
patients aged more than 23 years were in paid employment, which was associated with 
higher HRQOL36. These rates are better than previously reported, and higher than that 
after adult transplantation of 27-50%38-40.  
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In adults after liver transplant, HRQOL remains impaired, with poor physical 
function despite normalization of liver function, limiting their ability to return to work39, 41. 
Reduced skeletal muscle mass and strength have been reported to affect HRQOL in other 
conditions so it is likely this will also be true after liver transplantation23. Limited exercise 
capacity was noted in adults post-transplant and was postulated to be due to failure of 
reversal of muscle loss after transplantation42. In children, decreased exercise tolerance 
has been reported after liver transplantation, and may be improved with physical training43. 
The development of post-transplant obesity compounds the poor physical function of 
transplant survivors. Increased prevalence of obesity and metabolic syndrome above that 
of the general population has been reported in adult liver transplant survivors44. The 
concept of “sarcopenic obesity” after transplant, where subjects are obese but have 
reduced lean body mass, is an area of developing interest in adult transplantation as it 
may portend metabolic syndrome10, 24. The prevalence of obesity in children after liver 
transplantation, and whether it is more than normal for age, is not clear. The North 
American SPLIT group recently reported prevalence of 17% obesity and 32% overweight/ 
obese, which is similar to the general USA paediatric population45, 46. It is likely that 
reduced BCM, sarcopenia and obesity will contribute to HRQOL post-transplant as they 
can all affect physical function and limit ability to work.  
 Short stature is an undesirable physical attribute with potential to affect HRQOL in 
children47, 48. Growth is therefore considered an important determinant of HRQOL for 
children with chronic disease. Persistent growth failure despite reversal of malnutrition and 
catch up growth has been reported after liver transplantation26, 34, 35, 49. Pre-transplant 
factors including height Z-score at transplant, age at transplant, gender, and underlying 
diagnosis have all been reported to be important in determining height growth26, 49-51. Other 
variables including donor age, post-transplant hepatic vein stenosis, and steroid dose have 
also been reported to be important determinants of growth in children52-54. There remains 
however, limited data on long-term growth after liver transplantation in childhood. Several 
studies have reported children to attain height around the 25-30th centile, 7-10 years after 
transplant34, 35, 54. This duration of review however does not allow for full growth potential 
as many children will not complete growth until aged 20 years. This is especially important 
for malnourished children with likely delayed bone age compared to chronologic age. 
Clearly, more studies with longer follow up in children are required to better characterise 
post-transplant growth.  
All these outcomes described including BCM, obesity, and growth, may be affected 
by malnutrition, either in the pre-transplant period, or if it persists after transplantation. 
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Early life malnutrition is now recognised to have long-term effects on body metabolism 
including development of obesity, hypertension, diabetes, metabolic syndrome, as well as 
on cognitive development28, 29, 55. The long-term impact of pre-transplant malnutrition on 
survivors of childhood liver transplant survivors has not been recognised and is hence not 
well described. There are also few studies on very long-term outcomes after childhood 
liver transplantation. This thesis therefore aims to examine several long-term outcomes, 
particularly those that may be affected by malnutrition, after liver transplantation in 
childhood.  
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PRELIMINARY DATA 
The Queensland Liver Transplant Service (QLTS) was inaugurated in 1985, with the first 
Australian survivor being a 2 year old girl transplanted by this service. In the early days of 
the program, patients were referred from other Australian states, including Western 
Australia and South Australia, as well as from Asia, New Zealand and the Pacific nations. 
Over time, as other countries developed their own programs, this demographic has 
changed to mainly Australian patients, predominantly Queensland and northern NSW 
residents, with occasional referrals from Northern Territory or the other states. The last 
overseas paediatric patient transplanted by QLTS was in 2002. Whereas all patients 
awaiting liver transplant have to be within a 2 hour drive of Brisbane, once they have been 
successfully transplanted, they are allowed to return home to regional centres, inter-state, 
or overseas after three months if they remain well.  
 Long-term follow up after this time can be difficult in this diverse cohort as most 
patients are subsequently managed locally. Contact from overseas and inter-state patients 
tends to be sporadic and ad hoc once they return home. While contact is maintained for 
most Australian children and a large number of Japanese children because QLTS ran 
outpatient clinics in Japan, there is limited or no contact with children from New Zealand, 
South-East Asia, and the other Pacific nations. Additionally, due to the vast geographic 
distances in Queensland and Australia, even some Australian children have been lost to 
follow up.   
 Preliminary review of some long-term outcomes after transplantation occurred in 
2001. The result of this review is included here as it led to the inception of this thesis. 
Outcomes examined were growth, renal function, bone mineral density (BMD), and 
hyperlipidemia. Only patients who were aged <18 years at transplant by QLTS were 
reviewed. We considered patients who survived at least 5 years after initial liver transplant 
to be long-term survivors. QLTS performed 203 transplants in 179 children aged <18 years 
between 1985 until end of 1996. 77% (138/179) of these patients survived >5 years 
although 8 patients subsequently died more than five years after transplant. The causes 
for late death in these long-term survivors included post-transplant lymphoproliferative 
disease (n=2), chronic rejection (n=2), sepsis (n=2), and 1 each from de novo malignancy 
(medulloblastoma), and disease recurrence. At the time of the review in 2001, 70% 
(130/179) of paediatric QLTS liver transplant survivors were alive.  
 The origin of the 138 long-term survivors, including the 8 who subsequently died, 
was interesting as only 51 were Australian. The rest were from overseas with 47 children 
from Japan, 25 from New Zealand, 8 from Hong Kong, 5 from Malaysia, and 1 each from 
 34 
Tonga and Hungary. There was no contact, nor any correspondence from either the family 
or their treating physicians for at least four years in 32 children, which effectively meant 
that they were lost to follow up by QLTS. 
 A cross sectional review of height attained was assessed in these long-term 
survivors. The most recent recorded height of these children was plotted onto centile 
charts for age and sex. These height centiles were then grouped (<3rd, 3-<25th, 25-<50th, 
50-<75th, 75-<97th, and ≥97th) and the number of patients in each centile group plotted. 
The reason for this grouping was to enable some idea of height distribution even though 
these children were at different intervals after transplant. Height data was available for 113 
patients (Figure 1). While the height distribution of our cohort followed that of the normal 
bell-shaped curve, the peak of the graph was skewed to the left and closer to the 25th 
centile than the 50th centile. Interestingly, Viner et al found mean height centile attained up 
to 7 years after liver transplantation was the 27th centile, which is consistent with our 
findings, even though only 14/105 of his cohort had reached their final height54. He also 
reported that height Z-score at transplantation and steroid dose to be significant factors in 
height recovery.  
We noted in this group of patients that there was a trend to increasing proportion 
still on steroids the lower their height centile (Figure 2). The proportion ranged from none 
in those whose height was >97th centile, to 38% (5/13) in those who were <3rd centile in 
height. While this review did not take into account age of patient or duration of time 
(beyond 5years) from transplant, it suggests ongoing steroid use may be significant in 
determining height recovery. At the time, QLTS had a policy of maintaining children on 
steroids for 5 years post-transplant to reduce the likelihood of developing chronic rejection 
and de novo autoimmune hepatitis. This policy was reviewed after the results of this 
analysis because of ongoing concerns with prolonged steroid use, and increased interest 
in steroid-free or early steroid withdrawal after transplantation in children.   
 Renal function in long-term survivors was also examined in this preliminary review. 
Their glomerular filtration rate (GFR) was estimated using the Schwarz formula, where 
GFR (ml/min/1.73m) = 40 x Height (cm)/serum creatinine (µmol/l). Renal function was 
considered normal if GFR >80 ml/min/1.73m, mildly impaired if GFR 31-80 ml/min/1.73m, 
moderately impaired if GFR 10-30 ml/min/1.73m, and severely impaired if GFR <10 
ml/min/1.73m. Concurrent height and serum creatinine measurements were available in 93 
patients (Figure 3). Most, 66% (61/92), had normal renal function and none had severe 
renal impairment. Mild to moderate renal impairment however was noted in 34% (32/93).  
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Nineteen patients proceeded to having actual measurement of GFR by nuclear 
imaging with DTPA (Tc99 diethylene triamine pentaacetic acid) scans. Table 1 shows the 
comparison between actual and measured GFR, clearly showing that calculated GFR 
tends to overestimate renal function. This is better demonstrated in a Bland-Altman Plot 
shown in Figure 4. While progression to end-stage renal failure was uncommon among 
these patients, deterioration in renal function was common and more likely with increasing 
duration of follow up (Figure 5). 
 Among the 51 Australian long-term survivors, 26 patients had DXA scans 
performed at the time of this review. No fractures after transplant were reported in this 
group. Three patients were noted to have Lumbar Spine BMD Z-score <-2.0, which is 
considered to be osteopenic by definition. One of these patients however had significant 
bone age delay (3.5 years), to explain his low reading. After correcting for this, 2/26 (8%) 
had lumbar spine osteopenia at long-term follow up.  
Lipid profile, iron studies, zinc, selenium and fat soluble vitamin levels were also 
tested in the surviving Queensland patients. Of the 24 patients who had blood testing 
performed, only one patient had evidence of hypercholesterolemia and hyperlipidemia. 
None of these patients however were overweight or obese, nor had developed diabetes. 
This may partly be due to judicious use of immunosuppressants at the lowest possible 
doses, or a reflection of their relatively young age. All had normal fat soluble vitamin, zinc 
and selenium levels. Two patients were iron deficient but had evidence of ongoing blood 
loss from varices in their small intestine, near their Roux-en-Y anastomosis of the bowel.  
These interesting preliminary findings lead to the inception of this thesis, with more 
detailed assessment of specific aspects of long-term outcomes. While renal function 
assessment was initially proposed at thesis inception, this outcome was abandoned when 
a significant number of potentially eligible patients refused to participate as they felt that 
the requirement for intravenous cannulation to do GFR measurement was too unpleasant. 
While they were happy for any non-invasive testing, including comprehensive and lengthy 
neuro-psychometric testing, any non-essential invasive procedures, was considered 
unacceptable for many. Many of the long-term complications described in adults including 
obesity, dyslipidemia, diabetes and metabolic syndrome have its origins in early life under-
nutrition according to Barker’s “thrifty phenotype” hypothesis, or the rate of recovery from 
malnutrition according to Lucas28, 29. With this in mind, this thesis was then undertaken to 
examine long-term outcomes after childhood liver transplantation specifically assessing 
aspects which may be affected by malnutrition. 
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Figure 1. Height distribution in long-term survivors 
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Figure 2. Ongoing steroid use and its effect on height in long-term survivors 
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Figure 3. Renal function and calculated GFR in long-term survivors 
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Table 1. Comparing measured (DTPA) to calculated (Schwarz formula) GFR 
 
Renal Function Measured 
(DTPA) 
Calculated 
(Schwarz) 
Normal (GFR >80) 53% (10/19) 74% (9/19) 
Mild Impairment (GFR 31-80) 47% (9/19) 26% (5/19) 
Moderate Impairment.(GFR 10-30) 0 0 
Severe Impairment (GFR <10) 0 0 
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Figure 4. Bland-Altman Plot of measured vs calculated GFR 
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Figure 5. Measured GFR with duration of follow up. 
 
Slope = -7.6ml/min/1.73m 
p= 0.002 
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AIMS 
The aims of this thesis were to describe and assess several medical outcomes, which 
potentially may be impacted by early childhood malnutrition, in long-term survivors of 
childhood liver transplantation.  
 
Specific Aim 1: Assess long-term longitudinal anthropometric changes, including height, 
weight, and Body Mass Index (BMI) after childhood liver transplantation.  
Patients in whom there were ≥2 measurements, of which one was ≥5 years after 
transplant, were eligible to ensure that the same patients were being followed 
longitudinally. Height and weight measurements, and BMI calculations were performed at 
the time of transplant (or listing if transplant measurements unavailable), 1 year, 5 years, 
10 years, and 15 years after transplant. Z-scores using WHO reference ranges were used 
to compare with the normal population. The prevalence of overweight and obesity were 
noted.  
 
Specific Aim 2: Assess the longitudinal effect of childhood liver transplantation on body 
cell mass (BCM).  
Body composition assessment, using Total Body Potassium (TBK) measurements, are 
recognised to be more accurate than standard anthropometric measurements in assessing 
the nutritional state of a person, especially in those with liver failure. BCM was calculated 
from TBK and adjusted for height raised to the power p, depending on gender 
(BCM/Heightp). Only patients who were >3 years post-transplant, resident in Queensland, 
and had pre-transplant TBK measurements were eligible to participate to enable 
assessment of longitudinal change. The effects of age at transplant, growth impairment, 
biliary atresia diagnosis, and steroid use on BCM/Heightp were assessed.   
 
Specific Aim 3: Assess bone mineral density (BMD) in long-term survivors after childhood 
liver transplantation 
Patients transplanted aged <18 years, surviving >5 years after initial transplant, with 
ongoing follow up in our centre were eligible. BMD assessment using DXA was performed. 
Pre-pubertal children also had wrist X-ray to assess bone age. The effects of steroid use, 
age at transplant, growth impairment, and BCM on BMD were also examined.  
 
Specific Aim 4: Assess cognitive function, emotional health and academic performance of 
school-aged long-term survivors after childhood liver transplantation 
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Patients who had survived >5 years after transplant, who were still attending school (i.e. 
aged 6-18 years), and resident in Queensland were eligible. Hearing and comprehensive 
neuro-psychometric testing were performed to assess cognitive, academic, behavioural 
and emotional function. Siblings in addition to population norms were used as controls to 
provide better information about the child’s potential within the context of their family.   
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LITERATURE SEARCH 
Specific Aim 1: Growth and anthropometry 
Successful liver transplantation is recognised to correct malnutrition and improve growth in 
children9, 20. Initial catch up growth in the first two years after transplant is well described 
and most marked in the malnourished, and those transplanted aged <2 years in most 
reports49, 50, 56. One dissenting study however reported improved growth in children aged 
>2 years, and recommended delaying transplant if possible until they were older57.  
Persistent growth failure however, despite reversal of malnutrition and catch up 
growth, was reported in early publications from the 1990s26, 49, 57. There did not seem to be 
further improvement in growth velocity beyond 2 years after transplant so most survivors 
did not achieve normal growth26, 58. Reported pre-transplant predictors of poor growth 
include age at transplant, height Z-score at transplant, primary diagnosis, and gender26, 51. 
Boys were reported to have better growth in two studies51, 54. Primary diagnosis was 
thought to be important with biliary atresia patients having better growth recovery than 
those with acute liver failure, tumours, or Alagille syndrome26, 51, 59. Kelly also reported that 
the best catch up growth was seen in the most severely growth retarded children at 
transplant, but they were less likely to achieve normal height27. In contrast, those who 
were not growth retarded at transplant had slower growth but likely achieved normal 
height27. The best reported height attained from these early studies was the 17th centile (Z-
score -0.99) at 4 years in 119 children57.  
In addition to these pre-transplant variables, donor characteristics and post-
transplant management have also been reported to affect growth. In a study of biliary 
atresia patients undergoing live donor transplant, poorer growth was found with increased 
donor age and with development of hepatic vein stenosis post-transplant on multivariate 
analyses52. Other post-transplant factors such as immunosuppression, especially steroid 
therapy, ongoing liver disease and malnutrition, and need for re-transplant have all also 
been described to affect growth49, 54, 56. Therefore multiple factors, both pre- and post-
transplant, can affect growth in children after transplant including underlying diagnosis, co-
existing malnutrition, increased energy requirements, impact of medication, and any 
ongoing illness60.  
 Most of these reports however described patients within the first 5 years of 
transplantation, with limited information on subsequent growth. An early report from 
Toronto of 83 children found only 5% of their cohort to be <3rd centile at 6 years post-
transplant53. They also reported an inverse correlation of height and height velocity with 
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total yearly steroid dose in the post-transplant years, with 40% of those who weaned off 
completely, having height >50th centile53. Viner et al then described gradual improvement 
in height Z-scores from -1.2 at transplant to -0.84 at 7 years post-transplant; with final 
height attained at Z-score -0.55, equivalent to the 27th centile54. The most important 
predictor of eventual height attained however, was height Z-score at the time of transplant, 
although age at transplant, post-transplant high dose steroids, poor liver function, and re-
transplantation were also associated with poorer growth recovery54. While this publication 
is frequently cited, the estimated final height attained was based on only 14 pubertal 
patients, transplanted at mean age 12.6 yrs, who did not achieve much improvement after 
transplant as their starting height Z-score was -0.6354. A longitudinal study from San 
Francisco of 96 patients also reported continued growth recovery for 7 years, but no 
further improvement to 9 years in children aged <2 years or >7 years at transplant51. This 
cohort achieved even better growth with mean height on the 50th centile at 7 years (Z= 0), 
but no further improvement to 9 years with Z-score -0.151. The children who were aged 
between 2 to 7 years at transplant however, who were most growth impaired with mean 
pre-transplant height Z-score -2.2, exhibited poor growth throughout the 9 year follow up 
and were worse after transplant with Z-score -3.7 at 9 years post-transplant51. This study 
also had small patient numbers at long-term follow up with 22 patients surviving 6 years 
and 8 patients to 9 years post-transplant.  Only two publications have described growth to 
10 years post-transplant. Avitzur et al from Canada described 32 patients at 10 year follow 
up and found their median height Z-score -0.65 with 14% (4/32) below 3rd centile34. The 
SPLIT group of 167 patients reported mean height Z-score -0.51, with 23% below the 10th 
centile35. They found that patients with height <10th centile were three times more likely to 
still be receiving steroids compared to those whose height was >10th centile35. Height Z-
scores and centiles attained in these studies were similar to that reported by Viner in his 
earlier report54.  
Growth however may not be completed until aged 20 years in normal children.  
Growth delay is also common in malnourished children so it is important to recognise this 
when monitoring children with chronic illness. Since most children requiring transplantation 
are malnourished, monitoring of growth until aged 20 years is required before being certain 
of final height attained. Unfortunately, there is virtually no information available on growth 
or anthropometric changes in children beyond 10 years after liver transplantation. The only 
study to describe growth beyond 10 years mainly reported on bone density in 15 adults 
who were transplanted as children in Minneapolis61. This group of 15 patients, at mean 12 
years post-transplant, had mean height Z-score -0.04, 49th centile. These findings are 
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much better than previously reported, and close to the population mean, even though 
more than half remained on low dose steroid therapy. These very encouraging results 
clearly require further validation from larger long-term studies of height and weight 
changes after transplant.  
Weight recovery after transplant is more rapid than height recovery and often 
normalizes within 12-18 months9. Saito et al reported even more rapid weight gain with 
normalization by 12 months but their cohort was less malnourished, with mean weight Z-
score -0.78 at transplant52.  In contrast, a smaller study from London, England reported 
minimal weight change from transplant Z-score -0.82 to -0.61 five years later20. Post-
transplant weight changes are less often described than height changes, presumably 
because weight is easily confounded by fluid shifts even though resolution of this is 
expected with normalization of liver function. Longitudinal weight monitoring however is 
important despite its limitation as it is an easily accessible measure of body mass change 
over time and enables quick comparison to the normal population. Limited data on long-
term changes are available. At 10 years post-transplant, the Canadian cohort was at 
weight Z-score -0.69, and the Minnesota group at weight Z-score -0.33 after 12 years34, 61. 
While these weight Z-scores are within the normal range, they remain below the 
population mean. In contrast, SPLIT data reported their cohort to achieve mean weight Z-
score -0.06, but worryingly 10% of this cohort were considered obese with BMI >95th 
centile35. Obesity is recognised to be increasing prevalent in both the general population 
and adult survivors of liver transplantation, so is another reason for long-term weight 
monitoring in these patients. This lack of data for both long-term height and weight 
recovery in liver transplant survivors resulted in the development of Specific Aim 1 of this 
thesis, which was to examine long-term anthropometry after childhood liver 
transplantation.  
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Specific Aim 2: Body composition and body cell mass 
Malnutrition is common in children with end-stage liver disease, particularly in those 
awaiting liver transplantation. Body composition studies, which are recognised to be more 
accurate and reliable than anthropometric measures, are useful in defining the nature of 
this malnutrition. Using TBK measurements, children with end-stage liver disease have 
significantly reduced BCM with mean TBK only 63% of that expected for age and sex2. 
Similarly adults with non-alcoholic cirrhosis also exhibit reduction in BCM and body fat62. 
Reduced fat free mass has also been reported in adults awaiting transplantation of liver, 
lung, and heart63-65. Malnutrition and reduced weight has long been known to impact on 
peri-transplant mortality in children9. The implication of malnutrition and reduced BCM prior 
to liver transplantation is now also recognised in adults to increase post-transplant 
morbidity and mortality11, 12.  
 After transplantation, with subsequent normalization of liver function, the 
malnutrition associated with organ failure is presumed to resolve. In children, body weight 
recovers rapidly and often normalises within 12 months of transplantation52. Height 
recovery is slower and continues for at least 7 years after transplant, but remains lower 
than normal, reaching the 27th centile54, 56. Body composition changes after transplantation 
are not well defined. Increased fat mass and reduced lean mass have been reported in 
both adults and children in the first two years after renal transplantation; with early steroid 
withdrawal a significant factor in fat accretion and reduced lean mass recovery66, 67. 
Similarly, increased fat and reduced lean mass were also noted in adults after heart, liver, 
and haematopoietic stem cell transplantation65, 68. In contrast, increased both fat and fat 
free mass were reported after lung transplantation with two-thirds achieving normal fat free 
mass 2 years post-transplant69. No further increase in fat free mass however was noted in 
males although females continued to improve up to 4 years post-transplant69.  
There is very limited information on body composition after liver transplantation. 
Early work with adult patients found reduction in BCM immediately after liver transplant, 
particularly in the first 5 months70, 71. Recovery after this time however is unclear as there 
are conflicting results. Plank et al. noted improvement in BCM at 12 months compared to 
pre-transplant levels in a comprehensive metabolic assessment of 14 adult patients70. In 
contrast, Hussaini et al found no further improvement after 5 months in 55 adult patients 
followed for 24 months after transplant despite increases in body weight71. They concluded 
that the increase in body weight after transplant was due to increase in fat mass71. There 
are two reports of body composition beyond 2 years of liver transplantation and both used 
phase angle (PA) derived from BIA to estimate BCM24, 25. Improved BCM was noted at 50 
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months post-transplant compared to pre-transplant but remained below healthy controls in 
a study of 42 German patients24. Body weight, BMI, and fat mass also increased after liver 
transplantation with 17% of this cohort noted to be obese by BMI definition24. Wagner et al 
from Austria, noted that the proportion of patients with malnutrition, defined by PA <5˚, 
significantly reduced from 82% in those within 5 years of transplant to 32% in those ≥5 
years post-transplant, with poor correlation of PA with  BMI25. Interestingly, mean PA (and 
therefore BCM) remained within the malnourished range for all patients regardless of time 
post-transplant despite increasing BMI. Surprisingly, the authors concluded this increase in 
BMI together with lack of improvement in PA was consistent with oedema rather than 
increased fat25. Whether these changes also occur in children after liver transplantation is 
unknown.  
There are few body composition studies in children after organ transplantation. Only 
one publication in the literature describes body composition after liver transplantation in 
childhood72. This study, using DXA to examine bone mineral density after transplantation, 
reported no change in lean mass in 9 children at 6 months after transplant72. In contrast, 
lean mass and fat mass both increased at 12 months after renal transplantation in 30 
children; with greater total body and trunk fat in those who remained on steroids compared 
to those who stopped steroids after 6 days67. Improvement in fat free mass, but no change 
in fat mass was noted on longitudinal DXA scanning in 41 children at 24 months after lung 
transplantation73. This group however did not exhibit growth recovery after transplant, had 
minimal change in height and weight Z-scores after transplant, and remained significantly 
malnourished at 2 year follow up with height Z-score -1.8 and weight Z-score -1.673. No 
other data on body composition after solid organ transplantation in childhood is available. 
Increased fat mass but reduced lean mass was also noted in 54 patients 7 years after 
haematopoietic stem cell transplantation in childhood74. There is no information on long-
term body composition after any type of organ transplantation in childhood.  
 The significance of body composition after transplantation, and nature of recovery 
from malnutrition, is of increasing relevance as adults are now recognised to have 
increased prevalence of obesity, hypertension, and diabetes after liver transplantation24, 32. 
Whether this can be altered by exercise, particularly resistance training, or by protein and 
other dietary supplementation is unknown. There is developing interest in the concept of 
sarcopenic obesity after transplant, where there is good weight recovery but no or limited 
skeletal muscle improvement, and increased fat mass10. Post-transplant sarcopenia is 
thought to predispose to metabolic syndrome and reduced quality of life after adult liver 
transplant23. It is unknown whether this is also a problem after transplantation in childhood. 
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While some recent reports suggest increased incidence of overweight and obesity in 
children after liver transplant, the prevalence remains similar to the normal population and 
below that reported for adults44, 45. 
Clearly more body composition studies in children are necessary to document the 
development of obesity, document the pattern of fat development, and to relate this fat 
patterning in childhood to its development in adult life16.  This is especially relevant for 
transplant survivors as this group are recognised to have increased prevalence of 
obesity24. This lack of knowledge on changes in body composition after transplantation, 
especially long-term data, led us to Specific Aim 2 of this thesis, where we aimed to better 
define the longitudinal changes in body cell mass after liver transplantation. 
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Specific Aim 3: Bone mineral density 
Children with end-stage liver disease are susceptible to osteopenia and fractures, 
presumably from a combination of malabsorption and malnutrition associated with chronic 
liver disease. Children awaiting liver transplantation were reported to have fracture 
incidence of 16.2% around the time of transplant, both before and immediately after with 
most, 74% (14/19), having no documented trauma and 89% (17/19) with evidence of 
metabolic bone disease on radiography75. Similarly adults with end-stage liver disease are 
also recognised to have decreased bone density and increased fracture risk76-78. 
Normalization of liver function and resolution of malnutrition after transplant would be 
expected to ameliorate this risk but unfortunately, published data does not show this.  
Transplant survivors are recognised to have increased risk of osteoporosis, with 
fracture rates up to 25-35% reported in adults in the first 6 months after liver 
transplantation79. Two conflicting studies in infants reported on bone mineralization in the 
first three months after transplant80-81. Argao et al reported initial decline in bone mineral 
content in the first 3 months after transplant in 9 infants but subsequent improvement from 
4 months with normalization within 11 months80. No correlation was found between serum 
vitamin D levels or prednisone dose with bone mineral content. In contrast, a Japanese 
study of 36 children aged <2 years with biliary atresia found improved bone mineral 
density (BMD) 3 months after transplant with subsequent further increase in BMD to 
normalize by 24 months; their cohort attaining mean BMD Z 0.1681. No correlation with 
steroid dose was again noted although low vitamin D and IGF-1 levels correlated with 
reduced BMD81. At 6 months after transplant, improvement of BMD and bone mineral 
content compared to pre-transplant measurements were reported in two small studies of 
nine and eleven children72, 82.  
These studies however describe the acute changes in BMD within the first 12-24 
months of liver transplantation in children. In adult patients, fracture risk reduces after the 
first post-transplant year, but has also reduced in more recent transplant eras to 
prevalence rates of 3.5-15%, possibly because of improved pre-transplant nutrition and 
reduced post-transplant steroid use83, 84. Nevertheless, long-term surviving adults continue 
to report increased fracture risk compared to the normal population32, 85. Longitudinal long-
term studies ideally, enable better delineation of BMD changes over time in liver transplant 
survivors.  
One of the earliest reports on longitudinal follow up found initial decrease in BMD at 
3 months post-transplant in 28 adults, but ongoing recovery at 12, 46 and 85 months, to 
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normalize and attain mean lumbar spine (LS) BMD Z -1.086. These changes in BMD over 
time were corroborated in a large longitudinal study of 360 adults with either primary 
sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) 87. They also found initial 
reduction in BMD within the first 4 months of transplantation, but subsequent recovery to 
24 months and ongoing recovery from 4 to 8 years after transplant with normalization of 
BMD in that time to reach mean LS BMD Z-score -0.81 at 8 years87. Important predictors 
for low BMD pre-transplant were low BMI, muscle wasting, female gender and increased 
age although none of these were significant in predicting low BMD post-transplant87. On 
multivariate analyses, diagnosis of PSC instead of PBC, shorter duration of disease, and 
higher post-transplant bilirubin were the only variables significantly associated with low 
post-transplant BMD87. Steroid dose, tacrolimus dose and number of rejection episodes 
were not significant87. The longest follow up reported in adults also found normal BMD 15 
years after transplant, with LS BMD Z-score 0.16, although fracture risk remains significant 
at 15%85. The LS BMD Z-score attained in this study is much better than that from the two 
previous longitudinal studies where despite “normalization”, remained reduced compared 
to the normal population at -1.0 and -0.8185-87.  
There are few long-term studies of BMD in children with most being cross-sectional 
and include children within the first 2 years of transplant. The largest study to date, of 109 
patients from Cincinnati, reported mean LS BMD Z-score -0.27 at median 5.8 years after 
transplant88. Significant predictors of reduced BMD were weight Z-scores at time of DXA, 
steroid exposure in the year preceding DXA, and time after transplant; and no correlation 
noted with age at transplant, biliary atresia diagnosis, or serum vitamin D levels88. The 
prevalence of reduced BMD was 7.3% in their population, with steroid exposure being the 
most significant factor in determining this88. In contrast, subsequent smaller studies from 
multiple centres including Toronto, Helsinki, Minneapolis and Italy all found no correlation 
with ongoing steroid use61, 89-91. The main difference between this study and the others 
however was the shorter duration of follow up at median 5.8 yrs, compared to 7-12 years 
for the others. Only the study from Minneapolis however excluded patients within the first 2 
years of transplant61.  
The most recent report, in a study of 52 Canadian children, examined cumulative 
steroid dose in the first year after transplant, in the year before DXA scan, and total lifetime 
exposure, and found no correlation with BMD, which reached mean Z -0.66, at median 7.8 
years after transplant89. No correlation was noted with primary diagnosis, vitamin D and 
calcium intake, serum vitamin D or parathyroid hormone level. The prevalence of 
osteopenia, defined as BMD Z-score <-2.0, was 5.8%, and 21% for post-transplant 
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fractures, with low BMI and shorter time from transplant being significant predictors89. 
Significant bone age delay of >1 year compared to chronologic age was noted in 37% 
(18/52) of this cohort although BMD calculations were corrected for bone age; they were 
also relatively short and attained height Z-score -0.7689. The only long-term longitudinal 
study in children found improvement in LS BMD from pre-transplant Z-score -2.18 to reach 
median Z-score -0.5 at 7.0 years after transplant in 40 patients90. At 7 year follow up, 22% 
remained osteopenic (BMD Z-score ≤-2.0) and 18% had asymptomatic vertebral fractures. 
Older age, i.e. >10 years, at transplant was the only significant variable, with gender, 
rejection episodes, underlying diagnosis, renal function, short stature, obesity, vitamin D 
levels and steroid exposure all being insignificant predictors of low BMD or vertebral 
fractures90. Normal BMD was also reported in a small Italian study of 18 children at median 
8.3 years after transplant with LS BMD Z -0.70 despite one third (6/18) still on steroid 
therapy. Only one patient in this cohort had osteopenia but he had chronic renal failure91. 
The longest follow up reported in children was a study from Minneapolis of 15 patients at 
mean 12 (range 4.4-16.7) years61. Mean BMD normalized but was lower than expected for 
the normal population with lumbar spine Z -0.41 and total body Z -0.92. No effect on BMD 
was noted from gender, pre-transplant cholestasis, age at transplant, time from transplant, 
anthropometry (height, weight, BMI), or steroid use at the time of DXA61.  
There are conflicting reports as to the significant predictors of long-term reduced 
BMD in children after liver transplantation. Time from transplant was significant in 4/5 
studies, but not in the one with the longest follow up61. This cohort was aged >17 years, 
and only included patients >4 years after transplant. All the other studies included patients 
within the first two years of transplant when episodes of rejection and medical 
complications are more likely88-91. Longitudinal adult studies suggest that the most rapid 
improvement in BMD after transplant is within the first two years, with slowing of this 
improvement thereafter despite continued gains up to 8 years later86, 87. This would 
therefore be consistent with the lack of significance of time from transplant in the study that 
excluded patients within the first two years of transplantation.   
Weight and BMI have been reported to be significant in the two largest paediatric 
studies88, 89. Body size is recognised to affect DXA results and allowances should be made 
for this in children92. Malnutrition, particularly in association with growth impairment, is 
associated with reduced BMD. Conversely, overweight and obese patients tend to have 
higher BMD93.  The persistent correlation of low weight Z-scores with low LS BMD Z-
scores despite bone age correction in both studies suggests ongoing malnutrition may be 
significant. No information on weight Z-score was provided in the Cincinnati paper but on 
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examination of their scattergram plot of weight Z-score vs. LS BMD Z-score, more than 
half their cohort had weight Z-score <0 with a substantial number with weight Z-score <-
2.0, suggesting ongoing malnutrition88. Low BMI and muscle wasting, often used as 
markers of malnutrition in adults, have also been reported to be predictors of low BMD87. 
The Canadian study in contrast, were better nourished with weight Z-score -0.17 at the 
time of DXA but somewhat short with height Z-score -0.76. Interestingly, this study found 
correlation of BMI Z-score to be significant as 42% (22/52) of their cohort were either 
overweight or obese89. An interesting study in 37 adults at mean 7.5 years post-transplant 
examined the effect of body composition on bone density after liver transplant and found 
significant correlation of lean mass with LS BMD Z-score although 62% of their cohort was 
overweight or obese by BMI calculation94. BMI was positively correlated with LS BMD, but 
no correlation noted with steroid use or time from transplant. They also reported 
osteopenia in 54% but their definition (Z-score ≤-1.0) was more stringent than 
conventionally used (Z ≤-2.0) 94. No other data is available on the effect of body 
composition, a more accurate assessment of nutritional state, with BMD.  
Age >10 years at transplant was a significant predictor of low BMD in the 
longitudinal long-term study90. This was also noted in the cross-sectional Canadian study 
although those aged >10 years had shorter mean follow time of 3.7 years compared to 8.1 
years in those transplanted aged <10 years89. This finding however was not found in the 
other studies, especially the Minneapolis cohort, who were older than usual at transplant 
with mean age 10.6 (1.6-18.4) yrs but still managed to normalise BMD many years later 
with mean lumbar spine Z-score -0.4161. The effect of age 10 years at transplant is 
concerning as this coincides with the onset of puberty in many children, and the start of the 
period of maximal bone accretion. Peak bone mineral density occurs in the early to mid 
20s just after completion of adolescence and final growth. In adults, BMD declines with 
age whereas young children can expect improvement with age, particularly with onset of 
puberty95. While most children are transplanted in early childhood prior to the onset of 
puberty, the persistence of malnutrition or use of high dose steroids during this important 
period may have a role in determining BMD attained in the long-term.  
 The lack of effect from steroid exposure in all except the largest of these paediatric 
studies is surprising. The early reduction in BMD, nadir at 3-4 months post-transplant, 
described in both adult and paediatric studies, is usually attributed to high dose steroid 
therapy immediately after transplant. The only study to show increase in BMD 3 months 
after transplant was the Japanese cohort of biliary atresia patients81. These patients 
however had exceptionally low mean LS BMD Z-score -3.4, even though weight Z-score -
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1.67 was comparable to other studies81. It is highly likely this cohort was severely 
malnourished prior to transplant so that improvement in liver function and resolution of 
malabsorption after transplant resulted in improved nutrition and thence BMD despite 
being on steroids. The lack of steroid effect on BMD in the long-term is possibly because 
many have either ceased steroids or are maintained on low doses only. There is some 
evidence that low dose steroid therapy has no effect on BMD in children96. In contrast to 
adults who have declining BMD with age, children can expect ongoing improvement and 
the use of low dose steroids may not be sufficient to inhibit the improvement in BMD 
associated with adolescence.  
These studies suggest that the development of osteopenia after transplantation is 
likely to be multifactorial with genetic predisposition, underlying disease, malnutrition, 
immobilization, hypogonadism and post-transplant medication all postulated to have a role 
in its development79. The main limitation of currently published data in children however is 
the inclusion of patients within two years of transplant, who remain susceptible to medical 
complications, and may still be recovering from the effects of malnutrition associated with 
end-stage organ failure. The only long-term study in children, which also excluded patients 
within the first two years of transplant, however is very small with 15 subjects so is unlikely 
to be sufficiently powered to demonstrate important variables. The lack of true long-term 
BMD data in children after liver transplantation resulted in Specific Aim 3 of this thesis, a 
cross-sectional study of BMD in long-term, i.e. >5 years, post-transplant survivors; and to 
examine whether BCM predicts BMD. 
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Specific Aim 4: Neurocognitive outcomes 
Malnutrition in childhood is recognised to affect long-term cognition despite recovery from 
the initial insult55, 97. These long-term deficits may be subtle depending on the severity and 
duration of malnutrition, and gross testing using IQ, school grades, or need for special 
education assistance may fail to detect these problems55, 97. Malnutrition is common in 
children with end-stage liver disease although resolution is expected once they have 
undergone successful transplantation. Children with end-stage liver disease are vulnerable 
to cognitive deficits and have been reported to have lower performance IQ compared to 
age-matched children with cystic fibrosis; with primary diagnosis, age of onset, duration 
and severity of disease all impacting on their performance98. Whether there is 
improvement in cognition after transplant, and with time especially in the long-term, is not 
clearly defined.  
Long-term cognitive functioning, academic ability, behaviour, and psychosocial 
function all impact on quality of life of liver transplant survivors and affect their ability to 
function within society. There are, unfortunately, limited and contradictory information 
published on these outcomes, particularly in the long-term. No significant improvement 
was noted in IQ scores one year after transplantation compared to pre-transplant in two 
longitudinal studies99, 100. Paediatric liver transplant survivors as a group have been 
reported to have lower IQ than their peers in several studies with follow up to 10 years 
post-transplant101-103. Of concern, a Canadian study reported only 46% of their cohort to 
have normal IQ with the rest having definite or borderline intellectual impairment104. A 
recent, large, multicenter study in children at least 2 years post transplant was more 
encouraging; reporting full scale IQ within the normal range, mean 94.7±13.5, but 30% of 
their cohort had intellectual impairment, and 4% were severely impaired with IQ <70105.  
IQ alone however, is not a good predictor of school performance and overall 
academic outcome. As with typically developing children, there can be poor correlation 
between intellectual functioning, as measured by IQ, and academic outcome in children 
after liver transplantation101. IQ scores fail to describe subtle deficits, and more focused 
neuropsychological testing is necessary to provide information on these specific deficits106. 
There are however conflicting reports on specific cognitive outcomes in children after liver 
transplantation. Visual-spatial deficits have been described in some studies of long-term 
survivors but not in others102, 107, 108. Krull et al. from Chicago examined 20 children, 2 to 9 
years post transplant, and found lower IQ scores and lower receptive language skills but 
no difference in academic achievement, visual-perception, and visual-spatial skills  when 
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compared to 15 controls with cystic fibrosis108. In contrast, Adeback from Stockholm found 
greater impairment in non-verbal rather than verbal performance, which directly conflicts 
with the findings from the Chicago study102.  Difficulty with mathematics has also been 
reported in school-aged children after liver transplantation101, 109. 
There is also conflicting information on academic outcomes in children after 
transplantation. Gilmour reporting on behalf of the North American based SPLIT 
Consortium reported 34% of children requiring special education assistance and 20% 
repeating a grade at school110. Interestingly, the best predictor for needing education 
support in this cohort was the requirement for it pre-transplant, Odds Ratio 22.5, which 
suggests that pre-transplant factors are important110. In contrast, a Belgian study reported 
only 2.2% of their cohort requiring special education with 92.5% attending school 
regularly111. While convenient and easier to measure, gross indicators such as appropriate 
school grades, requirement for educational support, and progression through school are 
not good indicators of achievement of skills and knowledge110-112. Stewart and her 
collaborators from Dallas in their seminal work from the early 1990s identified that these 
children may have subtle cognitive impairments despite relatively normal albeit in the lower 
range intellectual functioning101, 107, 113. These contrasting findings and lack of specific 
rather than gross overall outcomes call for further studies examining long-term cognitive 
and academic functioning of patients who have undergone liver transplantation in 
childhood. 
There is again limited and conflicting information on psychosocial outcomes after 
liver transplantation. Several studies have reported the majority of their long-term survivors 
to have normal range of competencies and behavioural problems with increasing 
competence the longer they are from transplant111, 114. Other centres, however, have 
reported up to 50% of children having adverse psychological reactions with more than 
50% having behavioural or emotional disturbances114, 115. Gritti et al report decreased total 
behavioural competency and increased externalizing behaviour including aggression and 
delinquency with 72% exhibiting immaturity of ego and drives115, 116. There were also more 
depressive feelings, anxiety, as well as lower parent reported quality of life than in other 
chronic illness including kidney transplant survivors112, 115, 116. More studies, especially 
those with long-term follow up, examining psychosocial function in this population are 
needed to identify risk factors for developing future psychological problems. 
There are methodological concerns with many of these outcome studies including 
small sample size, variation in the types of tests used, and a general lack of long-term 
data106, 112, 117. Additionally, the timing of assessment and age at testing has been different 
 57 
making comparisons between centres difficult, which may contribute to these conflicting 
and confusing results. The timing of testing in these children is significant as those tested 
within the first three years after transplantation may still have medical and surgical 
problems impacting on their cognitive performance. Intellectual functioning also has been 
reported to improve with time21, 112. The age at assessment may also impact on these 
outcomes with some studies examining patients as young as 4 years and as old as 25 
years; which in most countries would not be considered school-aged102, 107, 111. The 
selection of an appropriate neuro-psychometric test is also dependent on the subject’s 
age, and extrapolation of findings between different tests for different ages may be 
problematic. Psychometric testing is expensive, time consuming and labour intensive, 
often requiring hours of one-to-one testing of subjects. The logistics involved in organising 
and undertaking these tests can be a deterrent to subject participation, which may be the 
reason for small sample sizes in many published reports. The use of common, widely 
available, age appropriate tools would enable multi-centre collaboration and meta-
analyses to better assess these outcomes despite small sample single centre studies.  
The lack of comprehensive neuro-psychometric assessment, and long-term data in 
children after liver transplant led to the development of Specific Aim 4 of this thesis where 
hearing and psychometric assessment of school-aged long-term survivors after liver 
transplantation was planned. In contrast to previously reported studies, siblings were used 
as controls, instead of the normal population or a cohort with chronic illness, to better 
characterise their underlying genetic potential.  
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RESULTS 
Specific Aim 1: Growth and anthropometry 
Ee LC, Beale K, Fawcett J, Cleghorn GJ. “Very Long-Term Growth and Anthropometry 
after Childhood Liver Transplantation” Journal of Pediatrics 2013; 163(2): 537-542. 
 
ABSTRACT  
Objectives: To describe longitudinal height, weight and body mass index (BMI) changes 
up to 15 years after childhood liver transplantation. 
Methods: Retrospective chart review of transplants from 1985 to 2004 was performed. 
Subjects were aged <18 years at transplant, survived ≥5 years, with at least 2 recorded 
measurements, of which one was ≥5 years post transplant. Measurements were recorded 
pre-transplant, 1, 5, 10, and 15 years later.   
Results: Height and weight data were available in 98 and 104 patients respectively. 47% 
were aged <2 years at transplant. 58% were Australian and the rest from Japan. Height 
recovery continued for at least 10 years to reach the 26th centile (Z-score -0.67) 15 years 
after transplant. Australians had better growth recovery and attained 47th centile (Z-score -
0.06) at 15 years. Weight recovery was most marked in the first year and continued for 15 
years even in well nourished children. Growth impaired and malnourished children at 
transplant exhibited the best growth, but remained significantly shorter and lighter even 15 
years later. No effect of gender or age at transplant was noted on height or weight 
recovery. Post transplant factors significantly impact growth recovery and likely caused the 
dichotomous growth recovery between Australian and Japanese children. 9% (9/98) of 
patients were overweight on BMI calculations at 10-15 years but none were obese.  
Conclusions: Children after liver transplant can expect ongoing height and weight 
recovery for at least 10-15 years. Growth impairment at transplant, and post transplant 
care significantly impact long-term growth recovery. 
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 INTRODUCTION 
Growth normalization is an important measure of long-term success in the treatment of 
any chronic childhood illness including liver transplantation. Poor growth after liver 
transplantation is well described with many authors describing failure of these children to 
reach normal height despite initial catch up growth following successful liver 
transplantation (1-3). To date, only short and medium term follow-up studies have been 
reported with a paucity of long-term data (1-5).  
Initial catch up growth is well described in the first two years after liver 
transplantation and is most marked in the malnourished, and children transplanted before 
two years of age (3-6). One study has also reported improved growth when the transplant 
was performed in children aged > 2 years (7). Superior growth recovery in boys has also 
been reported (5, 8). The initial causative pathology is also thought to play a role in 
subsequent growth with poorer recovery reported in those with acute liver failure, tumours, 
or Alagille’s syndrome (1, 8-9). In contrast, using multivariate analysis, a report of patients 
with biliary atresia following live donor transplant, described poorer growth with increased 
donor age and the development of hepatic vein stenosis post transplant (10). Therefore, a 
multitude of pre and post transplant factors can affect growth in children after transplant 
including the underlying diagnosis, co-existing malnutrition, increased energy 
requirements, impact of medication and any ongoing illness (11).  
Biliary atresia remains the most common reason for liver transplantation in children. 
All cholestatic diseases, of which biliary atresia is the most common, result in 
malabsorption and increased energy and nutritional requirements but these are expected 
to resolve with successful transplantation. Weight recovery tends to be more rapid and will 
often normalize within a year of transplant even among the malnourished (10, 12). These 
observations appear to be independent of the pre transplant weight possibly being 
confounded by fluid retention and ascites.  
Height recovery tends to be delayed compared to weight and is likely to be further 
affected by post transplant factors. Height recovery has been reported up to 7 yrs after 
transplant although the final height attained was only at the 27th centile (3, 5). Growth 
however may not be completed until aged 20 years in normal children and it is important to 
recognise this when monitoring infants and those with delayed bone age.  With correction 
of malnutrition after transplant, ongoing height recovery beyond seven years would have 
been expected as long as their post transplant course is uncomplicated. One may then 
speculate that post transplant management, including steroid use and graft function may 
have a greater role in determining final height attained than previously recognised.  
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There is currently very limited information available on height and weight changes in 
children beyond 10 years after liver transplantation. A small study from USA looking mainly 
at long-term bone density noted that 15 young adult subjects who were transplanted in 
childhood, had mean height Z-scores of 0.04, which is approximately the 51st centile (13). 
This is higher than previously reported and occurred even though more than half remained 
on low dose steroid therapy. These results require further validation from larger studies.  
The development of obesity following liver transplant is a significant clinical problem 
for adult recipients with up to half developing metabolic syndrome in some centres (14, 
15). It remains unclear whether those transplanted as children will also develop obesity. 
Weight changes traditionally have not been examined in most long-term studies as they 
can be affected by drugs, fluid retention, and ascites among other factors. The increasing 
incidence in obesity in the general population however will likely change this. A recent 
report from the North American SPLIT (Studies of Pediatric Liver Transplantation) 
Research Group, using Body Mass Index (BMI) measurements reported 18% and 11% of 
their cohort were obese at 3 and 5years post transplant respectively (16). The rate of 
obesity at 5years post transplant however was similar to the 2003-2004 NHANES 
population data (16).   
The aim of this study was therefore to describe longitudinal anthropometric (height, 
weight and BMI) changes seen in children having received a successful liver transplant up 
to 15 years previously.  
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MATERIALS & METHODS  
The Queensland Liver Transplant Service (QLTS) commenced in 1985 and has performed 
317 transplants in 269 children up till 31st December 2011. In the early years, many 
overseas patients were transplanted by our service until the development of their own 
paediatric transplant programs. Retrospective chart review was performed on all patients 
transplanted between 1985 and 31 December 2004. Children surviving at least 5 years 
after initial transplant were considered long-term survivors. Only those in whom there were 
at least two measurements, of which one was ≥ 5 years post transplant, were included to 
ensure that patients were analysed longitudinally. This study was approved by the Ethics 
Committee of Royal Children’s Hospital, Brisbane, where QLTS is based. 
Time points of interest were: at transplant (time zero), 1 year, 5 years, 10 years, 
and 15 years after liver transplant. In the pre transplant patients, measurements on the 
day of transplant or a date as close as possible to this were recorded. With follow up 
measurements, those as close as possible to the anniversary of transplant were used. 
Height and weight measurements were recorded at these time points as described. BMI 
was calculated for all patients using height and weight measurements for the same time 
intervals where BMI = Weight (kg)/Height (cm)2. Height, weight, and BMI age and sex 
adjusted Z-scores were calculated based on World Health Organisation (WHO) Child 
Growth Standards 2006 and WHO reference 2007 charts. Subjects aged ≥ 18 years were 
considered overweight if their BMI was ≥ 25 and obese if BMI ≥ 30. Children aged <18 
years were considered overweight using a BMI reference table based on an international 
survey from 6 countries by Cole et al, which corresponds approximately to 90th centile BMI 
for overweight and 99th centile for obese (17).  
Patients were analysed as a group but also divided by gender, age at transplant, 
country of residence, and whether they were malnourished or growth impaired at the time 
of transplant. As malnutrition at the time of transplant has been reported to cause 
persistent growth failure, we subdivided the cohort into those with Z scores either below or 
above the 10th centile (equivalent to Z-score -1.28) at time of transplant to see if there was 
any difference in growth recovery. We considered patients to be growth impaired or 
malnourished when their height or weight Z-score was < -1.28, corresponding to the 10th 
centile respectively. Statistical analyses were performed using the SPSS statistical 
package. Student’s t- test, Fisher exact test and Mann-Whitney tests were used in the data 
analyses. Results were considered significant if p-value was <0.05. 
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RESULTS 
228 children aged <18 years were transplanted by QLTS between 1985 to 31 December 
2004. 78% (178/228) survived at least 5 years after initial transplant although 15 patients 
subsequently died more than 5 years after transplant. 98 patients were eligible to be 
included with at least 2 height measurements, of which one was ≥ 5 years after initial 
transplant. There was 94% (92/98) cohort retention at 5 years, 91% (89/98) at 10 years 
and 49% (48/98) at 15 years after transplant. Somewhat surprisingly, only 55% (54/98) 
had measurements recorded 1 year after transplant. Thirteen children (10 Australian and 3 
Japanese) had more than one transplant but survival was calculated from time after initial 
(first) transplant. Cyclosporine based immune suppression was used in all patients until 
1994 when this was changed to tacrolimus. All patients were maintained on low dose 
steroid therapy for at least five years after transplant for those on cyclosporine and at least 
two years for those on tacrolimus as was QLTS policy at the time.  
Patient demographics are shown in Table 1.1. There were slightly more Australian 
than Japanese patients and almost half (47%, 46/98) were aged < 2 years at transplant. 
Significant differences noted between Australian and Japanese patients include younger 
age at transplant in Australians (p<0.0001), more biliary atresia in Japanese patients 
(p=0.014), and more Japanese patients below 10th centile for height (p=0.014), but not 
weight at the time of transplant. Some of the height effect may be due to ethnicity even 
though WHO growth standards, which are based on multiracial cohorts, were used. All 
children with Alagille syndrome, alpha-1-antitrypsin deficiency and acute liver failure were 
Australian.  
Height measurements were available in 98 eligible children. All children had 
ongoing height recovery up to 10 years but no further improvement at 15 years after 
transplant (Table 1.2). Gender and age at transplant did not affect height recovery. Growth 
of children aged < 2 years paralleled that of older children with no significant difference in 
Z-scores at any stage. Australian children had better and more sustained height recovery, 
which continued up to 15 years post transplant with mean height attained on the 48th 
centile (equivalent to Z-score -0.06) at 15 years. Japanese children, who were significantly 
shorter than Australian children at all time points except 1 year post transplant, also 
exhibited growth recovery to 10 years but did not sustain it at 15 years.  The best height 
achieved by Japanese children was the 12th centile (Z-score -1.14) at 10 years post 
transplant.  
When the growth impaired cohort (height Z-score < -1.28, i.e. <10th centile) was 
compared to the rest of the group, there were clear differences in their recovery (Figure 
 63 
1.1). Although growth impaired children demonstrated the greatest height recovery, they 
continued to be significantly shorter at all times than those who were not growth impaired 
at transplant. Australian patients reached mean height of 60th centile (Z-score 0.23) for 
normal and 30th centile (Z-score -0.53) for growth impaired patients at 15 years after 
transplant. This difference was not quite statistically significant although it was at all 
previous time points. The Japanese growth impaired children also had good height 
recovery in the first year similar to Australian children but in contrast, had minimal 
improvement at 10 years, then dropped off at 15 years. The best mean height centile 
attained by these children was 7th centile at 10 years, but only 2nd centile at 15years. 
Japanese children who were not growth impaired at transplant however, had the least 
growth recovery and did worse after transplant at all times except in the first year. While 
they started on the 33rd centile (Z-score -0.44) at transplant, height attained was 30th 
centile (Z-score -0.49) at 10 years and 12th centile (Z-score -1.14) at 15 years. Clearly 
ethnic differences and malnutrition are not sufficient to explain this poor growth in 
Japanese children and implicate post transplant factors as the cause. No difference was 
noted in height Z-scores at any time between patients with multiple transplants and those 
with one transplant for all kids and for the Australian cohort (data not shown). 
Weight measurements were recorded in 104 children (Table 1.2). All patients had 
weight recovery, which was most marked in the first year, up to 15 years post transplant. 
There was no difference in weight recovery between boys and girls nor was the difference 
in their mean weights statistically significant. Children aged < 2 years at transplant had the 
greatest recovery in the first post transplant year but thereafter had similar Z-scores to 
older children. There were significantly more malnourished children in those aged <2 years 
at transplant with double the proportion compared to well nourished children (data not 
shown). Australian children demonstrated significantly better weight recovery than 
Japanese children beyond 1 year although there was no difference at transplant and 1 
year post transplant.  
Children who were malnourished at transplant (weight Z-score < -1.28, ie <10th 
centile) remained significantly lighter than well nourished children at all times even though 
they exhibited the most recovery to reach the 30th centile at 15 years (Figure 1.2). As 
expected, well nourished children exhibited little weight Z-score gain over the years, 
although still increased their mean weight from 44th centile at transplant to 55th centile 15 
years later. There was no difference in weight recovery between Australian and Japanese 
well nourished patients. Japanese malnourished patients had poor weight recovery after 
the first year with best weight attained being 14th centile at 15 years. In contrast, 
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malnourished Australian patients had ongoing weight recovery and reached the 49th 
centile at 15 years even though significant differences from Japanese patients were only 
noted at 10 and 15 years after transplant.  
BMI was calculated only in patients with concurrent height and weight 
measurements. Mean BMI Z-scores were essentially unchanged at long-term follow up to 
15 years (Table 1.2). Girls had higher mean BMI Z-scores than boys at all times, but this 
was only statistically significant at transplant (p=0.015), and 10 years later (p=0.023). No 
difference in BMI Z-scores were noted between children aged <2 years at transplant with 
older children except at the time of transplant (p=0.001). This is consistent with the 
younger children being more malnourished than older children at the time of transplant. 
Even though Australian children had better height and weight recovery, there was no 
significant difference in mean BMI Z-scores when compared to Japanese children.  
Eight patients were noted to have BMI ≥ 25 and considered overweight at 10-15 
years after transplant although none had BMI ≥ 28. All these patients were aged ≥ 18 
years. When BMI reference tables were used for those aged <18 years, an additional child 
was considered overweight. No patient had BMI within the obese range. These results 
show 9% (9/98) of our cohort to be overweight at 10-15 years post transplant but none 
were obese. Of these 9 patients, 8 were already overweight at 5 years post transplant 
although not all patients who were overweight at 5 years (n=13) remained overweight at 
their latest review at 10-15 years.  
We were unable to assess total steroid dosing for individual patients as most 
patients, especially the Japanese cohort, were no longer managed by our service and only 
limited information on their care was available. The dichotomous growth between 
Australian and Japanese patients, most marked after the first year, strongly suggests that 
post transplant care is important in determining ongoing growth as this difference in 
insufficiently explained by diagnosis, age, and degree of malnutrition or growth impairment 
at transplant. Interestingly, patients with multiple transplants, suggestive of initial poorer 
graft function, did not have significantly reduced height Z-scores at all time points but there 
were only 13 patients (13%) in this group. We did not attempt to assess the effect of 
underlying diagnosis on growth as the predominant diagnosis in our cohort was biliary 
atresia and there were insufficient patient numbers with other diagnoses to analyse.   
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DISCUSSION 
Our results demonstrate ongoing height and weight recovery up to 15 years after 
childhood liver transplantation. The mean height attained 15 years after transplant was the 
26th centile (Z-score -0.62), similar to that previously reported by Viner (5). Australian 
children however reached the 47th centile (Z-score -0.06), which is close to the population 
normal. The effect of growth impairment at transplant remains significant many years later 
with these children never quite catching up to their normally grown peers despite exhibiting 
the best growth over 15 years. We did not see any effect of gender or age at transplant on 
height recovery and postulate that previous reports of it being significant may actually be 
due to growth impairment at time of transplant. Surprisingly, we did not see any difference 
in height in those requiring repeat transplantation. This may however be due to the small 
number of patients in our cohort, duration of ill health, and timing of subsequent 
transplants.  
Weight recovery was most evident in the first year after transplant particularly in the 
malnourished. Despite this, they never attained the weight of their well nourished peers 
despite presumed correction of malnutrition after transplant. The marked weight recovery 
noted in those aged < 2 years at transplant is likely because they were more malnourished 
at the time of transplant. Growth of these children seems to parallel those transplanted at 
an older age after the initial first year of greatest catch up. Many of these children however 
are still adolescents and undergoing puberty, which is a period of rapid growth. It is 
possible these children may continue to improve their height and weight percentiles 
beyond the timing of our study.  
The difference in growth recovery between Australian and Japanese children is very 
interesting. While there may be ethnic differences in height potential, using similar growth 
charts allowed us to compare growth patterns and Z-scores. Although Japanese children 
were significantly shorter prior to transplant, their growth rate after transplant was 
attenuated compared to Australian children. Even though both groups improved after 
transplant with no statistical difference in mean height Z-scores between them at 1 year, it 
diverged again in the long-term and was especially marked 15 years after transplant. 
Australian children grew from mean height of 18th centile (Z-score -0.92) at transplant to 
47th centile (Z-score -0.06) 15 years post transplant. In contrast, Japanese children 
essentially remained at the 4th centile (Z-score -1.74) pre transplant and 15 years (Z-score 
-1.64) later with their best mean height on the 13th centile (Z-score -1.1) at 1 year post 
transplant. When we compared the growth impaired children at transplant to those that 
were not, this growth differential was even more marked with Japanese children who were 
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not growth impaired at transplant exhibiting the worst growth. These children in fact 
demonstrated declines in their height from the 33rd centile (Z-score -0.44) at transplant to 
the 12th centile (Z-score -1.14) 15 years later. This decline, not seen in the other 
subgroups, is strongly suggestive of the impact of post transplant factors on growth.  
Weight changes were less marked between Australian and Japanese patients with 
no difference in the proportion of malnourished patients at transplant. Significant 
differences between Australian and Japanese patients were only noted at 10 and 15 years 
after transplant in the malnourished group. This again suggests the effects of post 
transplant care as these differences are not sufficiently explained by malnutrition at the 
time of transplant.  
The significant differences noted between Australian and Japanese patients in 
addition to ethnicity were age at transplant, diagnosis of biliary atresia, and growth 
impairment at time of transplant. Our results showed no apparent difference in growth in 
those aged <2 years at transplant, and even less so when malnutrition as factored in. 
While more Japanese patients had biliary atresia as their diagnosis, previous studies 
indicate that this is associated with more favourable growth outcomes compared to other 
diagnoses and so is unlikely to be the cause of the dichotomous growth in our cohort. 
Japanese patients were also more growth impaired at transplant compared to Australians. 
Whether this is partly a racial characteristic is difficult to ascertain but we attempted to 
avoid this by using WHO growth charts based on multiracial populations. Nevertheless, 
their pattern of growth recovery for both height and weight is significantly different to 
Australian children. If initial growth impairment was from ethnic differences, we would have 
anticipated similar growth patterns but at lower percentiles. Instead the Japanese patients 
had reduced height and to a lesser extent weight recovery which became more marked 
over time. This pattern is strongly suggestive of post transplant factors, and most likely 
steroid use as the cause of this attenuated growth as has previously been described.  
The era of transplantation may play a role in this difference as nearly all the 
Japanese were transplanted before 1996 with only four patients being transplanted after 
that time. In contrast, Australian patients were transplanted throughout the life of the 
service through all eras. Better surgical and operative techniques, newer drugs and 
regimes, and increasing awareness of steroid and other drug effects on growth all may 
have a role. An additional aspect of postoperative care is whether paediatricians are 
involved. Different specialities often have different priorities in complex patient care with 
surgeons and adult physicians invested in maintaining good graft function; while 
pediatricians are additionally concerned about growth and nutrition. While we are unable to 
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define the extent of significance in our cohort, Japanese children were mainly managed by 
transplant surgeons and adult physicians but not paediatricians, whereas Australian 
children usually had paediatricians continue to be involved in their care until they reached 
adulthood.  
BMI calculations have been used as an indicator of overweight and obesity in 
adults. In general, patients are considered overweight if BMI ≥ 25 and obese if BMI ≥ 30, 
although there is some variance depending on ethnicity. In children, this is less well 
defined as BMI is recognised to change with age and there is significant controversy as to 
the best method to define obesity. The International Obesity Task Force, using population 
surveys from six countries, developed a table that back-extrapolates BMI cut offs so that it 
coincides with BMI 25 for overweight and BMI 30 for obese at aged 18 years, the accepted 
adult standards (17). Using this table, 9% of our patients are overweight at 10-15 year 
follow up although none were obese. This rate however remains lower than the population 
where 17% of Australian children aged 5-17years were overweight and 8% obese in 2007-
2008 (18).  It is likely however that this proportion will increase in time. Further monitoring 
will be necessary and better anthropometric measures and agreement on definitions 
should be used to determine if these children are at high risk of developing obesity like 
adult transplant recipients.  
This study is the first to report ongoing height and weight recovery up to 15 years 
after liver transplantation in childhood. Similar to previous reports, patients can expect to 
attain the 26th centile height at 15 years although Australian children are likely to reach the 
normal population mean. This study also clearly shows the long lasting effects of growth 
impairment and malnutrition at the time of transplant with failure of these children to catch 
up even at 15 years after transplant despite exhibiting the best growth rates. We also did 
not note any effect of gender or age at transplant on height and weight recovery and 
postulate that previous reports demonstrating it is likely to be related to degree of 
malnutrition. Our dichotomous results between the Australian and Japanese patients also 
clearly show that post transplant care is also very significant in affecting final height 
attained. While we were unable to quantify the amount of steroids used in our cohort, this 
is likely to be the most important post transplant factor affecting growth.  
These outcomes for growth are better than previously reported and highly 
encouraging for patients and gratifying for the transplant community. It is likely that with 
shorter duration of steroid use, better post transplant care, and improved nutritional 
management pre and post transplant, that the growth potential of these patients will be 
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even better. Close monitoring however is required as to whether these patients are at risk 
of developing obesity in later life.  
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Table 1.1: Patient Demographics 
 
 TOTAL AUSTRALIAN JAPANESE p value 
Number of patients 98 57 41  
Boys 37 25 12 ns 
Girls 61 32 29 ns 
Median age at 
transplant 
(years, range) 
2.0 
(0.08-17) 
1.37 
(0.08-14.17) 
3.12 
(0.83-17) 
<0.0001 
Aged <2yrs at 
transplant 
46 34 12 0.0037 
DIAGNOSES     
Biliary atresia 76 39 37 0.014 
Alagille syndrome 5 5 0  
Alpha-1-antitrypsin 
deficiency 
4 4 0  
Acute Liver Failure 3 3 0  
Miscellaneous 10 6 4  
Height Z < -1.28 at 
OLT 
45 20 25 0.014 
Weight Z < -1.28 at 
OLT 
45 23 21 ns 
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Table 1.2: Mean Height, weight and BMI Z scores over time (n patients) 
 Pre OLT 1 yr post 5 yr post 10 yr post 15 yr post 
HEIGHT      
All -1.26 (98) -0.89 (54) -0.99 (92) -0.57 (89) -0.62 (48) 
Boys -1.3 (37) -0.87 (24) -1.19 (31) -0.60 (30) -0.62 (19) 
Girls -1.24 (61) -0.87 (30) -0.88 (61) -0.50 (59) -0.62 (29) 
<2y at OLT -1.41 (46) -0.85 (23) -0.99 (41) -0.55 (44) -0.61 (27) 
≥2y at OLT -1.13 (52) -0.92 (31) -0.99 (51) -0.59 (49) -0.64 (21) 
Australian -0.92 (57) -0.79 (37) -0.52 (49) -0.13 (50) -0.06 (31) 
Japanese -1.74 (41) -1.1 (17) -1.53 (43) -1.14 (39) -1.64 (17) 
OLT Ht<-1.28 -2.52 (45) -1.69 (23) -1.63 (42) -1.15 (43) -1.19 (22) 
OLT Ht≥-1.28 -0.18 (53) -0.27 (31) -0.46 (50) -0.03 (46) -0.14 (26) 
WEIGHT      
All -1.03 (104) -0.46 (80) -0.56 (99) -0.47 (92) -0.20 (48) 
Boys -1.24 (37) -0.56 (31) -0.84 (36) -0.66 (32) -0.40 (16) 
Girls -0.92 (67) -0.40 (49) -0.39 (63) -0.37 (60) -0.11 (32) 
<2yr at OLT -1.57 (49) -0.51 (36) -0.53 (45) -0.50 (44) -0.14 (27) 
≥2yr at OLT -0.56 (55) -0.41 (44) -0.58 (54) -0.44 (48) -0.28 (21) 
Australian -0.87 (61) -0.34 (45) -0.29 (54) -0.16 (54) 0.14 (29) 
Japanese -1.27 (43) -0.62 (35) -0.88 (45) -0.91 (37) -0.72 (19) 
OLT Wt<-1.28 -2.22 (45) -1.03 (35) -1.01 (44) -0.91 (45) -0.51 (25) 
OLT Wt≥-1.28 -0.13(59) -0.02 (45) -0.20 (55) -0.04 (47) 0.13 (23) 
BMI      
All -0.10 (98) 0.50 (53) 0.15 (92) -0.12 (91) -0.11 (49) 
Boys -0.65 (38) 0.10 (24) 0.01 (32) -0.4 (31) -0.31 (18) 
Girls 0.25 (60) 0.84 (29) 0.23 (60) 0.04 (60) 0.01 (31) 
<2yr at OLT -0.54 (46) 0.34 (23) 0.31 (41) -0.10 (44) 0.07 (26) 
≥2yr at OLT 0.29 (52) 0.62 (30) 0.03 (52) -0.14 (46) -0.31 (23) 
Australian -0.16 (57) 0.52 (37) 0.27 (49) 0.06 (52) -0.04 (30) 
Japanese -0.01 (41) 0.47 (16) 0.02 (43) -0.35 (39) -0.22 (19) 
BMI= Body Mass Index, OLT= Orthotopic Liver Transplant 
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Figure 1.1: Height Z-scores over time between growth impaired and normal children 
 
 
All= All patients; Au = Australian residents; Ja = Japanese residents; GI= growth impaired  
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Figure 1.2: Weight Z-scores over time between malnourished and normal children 
 
 
 
All= All patients; Au = Australian residents; Ja = Japanese residents; M=Malnourished 
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Specific Aim 2: Longitudinal body cell mass 
Ee LC, Hill RJ, Beale K, Noble C, Fawcett J, Cleghorn GJ. “The long-term effect of 
childhood liver transplantation on body cell mass” Liver Transplantation 2014; 20(8): 922-
929. 
 
ABSTRACT  
Objective: Malnutrition is common in end-stage liver disease but correction after 
transplant is expected. Body cell mass (BCM) assessment using total body potassium 
(TBK) measurement is considered the “gold standard” for assessing nutritional status. The 
aim of this study was to examine BCM and therefore nutritional status of long-term 
survivors after childhood liver transplantation.  
Methods: Longitudinal nested cohort study of patients transplanted aged <18 years, 
surviving >3 years, with ongoing review at our centre. TBK measurements were obtained 
pre-transplant, and at long-term follow up. BCM was calculated from TBK and adjusted for 
height raised to the power p depending on gender (BCM/Heightp). The effect of age at 
transplant, linear growth impairment, biliary atresia diagnosis, and steroid use were 
assessed.   
Results: 32 patients, 20 males, participated. 62% had biliary atresia. Median age at 
transplant was 2.11 (range 0.38-10.92) years. Post-transplant testing was performed at 
median 7.23 (range 3.28-14.99) years when they were aged 10.12 (range 4.56-20.77) 
years. This cohort attained mean (±SD) Z-scores for height -0.41 (±1.36), weight -0.26 
(±1.14), and body mass index 0.04 (±0.99). BCM/Heightp was reduced pre-transplant but 
further reduced post-transplant (p<0.001) despite normalization of height and weight. 
Weight recovery is therefore likely from increased fat mass, not BCM. Linear growth 
impairment was associated with greater reduction in post-transplant BCM/Heightp 
(p=0.02). On multivariate analyses, only older age at transplant predicted reduced post-
transplant BCM/Heightp (p=0.02). Gender, age at transplant, steroid use, and underlying 
diagnosis, did not predict change in BCM/Heightp after transplant. 
Conclusions: Weight recovery in long-term survivors of childhood liver transplant is likely 
due to increased fat mass since BCM remains reduced. Nutritional compromise persists in 
long-term survivors of childhood liver transplant. 
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INTRODUCTION 
Malnutrition is common in children with end-stage liver disease, particularly in those 
awaiting liver transplantation due to a combination of factors which include hypermetabolic 
state, inadequate intake, and malabsorption from cholestatic liver disease. Previous work 
from our centre has shown that malnourished children have reduced survival after liver 
transplantation (1). The nature of malnutrition in end-stage liver disease has been reported 
to be from a combination of reduction in body fat and protein stores, severely depleted 
body cell mass, as well as deficiencies in fat soluble vitamins, iron, zinc, and selenium (2).  
The assessment of malnutrition however can be difficult in patients with end-stage 
liver disease and standard anthropometric measures are recognised to be inaccurate in 
assessing nutrition in this group. Traditional measures including subjective global 
assessment, weight, and body mass index (BMI) calculations tend to underestimate the 
degree of malnutrition in both children and adults when compared to body composition 
analyses (3, 4). Total body potassium (TBK) measurement is considered the “gold 
standard” for assessing body cell mass (BCM), the metabolically active component of fat 
free mass. It is not affected by extracellular fluid shifts, edema, ascites, or diuretic use, all 
of which are significant in solid organ failure, and is hence a useful and reliable measure of 
body composition, and of the functional nutritional status of the person.  
With successful transplantation, one anticipates correction of pre-transplant 
malnutrition and improved growth in children. Body weight is recognised to correct rapidly 
and normalise within 12 months of transplantation, but ongoing recovery occurs even up to 
15 years later (5). Height recovery, however, is slower but can also occur up to 15 years 
after transplant although this may be incomplete in growth retarded children, and further 
attenuated by post-transplant management (5). The nature of recovery from malnutrition 
after transplant, in body composition terms, however remains unclear.  
There is limited information on body composition after liver transplantation, 
particularly in long-term survivors. Adult studies have shown reduced BCM in the first five 
months after liver transplantation, but conflicting reports on subsequent improvement 
thereafter (6, 7). Hussaini et al found no further improvement in BCM up to two years after 
transplant, and concluded that the weight recovery noted was likely due to increased fat 
(6). Obesity is a significant problem for adult patients after liver, kidney, and hematologic 
stem cell transplant (8).  In adults, there is developing interest in the concept of sarcopenic 
obesity after transplant, where there is good weight recovery, but no or limited skeletal 
muscle increase, and increased fat mass (9). It is unknown whether this is also a problem 
after transplantation in childhood. While some recent reports also suggest increased 
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incidence of overweight and obesity in children after liver transplant, the prevalence 
remains similar to the normal population and below that reported for adults (10, 11). 
The aim of our study, therefore, was to assess whether there were any changes in 
body composition, through TBK measurement of BCM, in long-term survivors of childhood 
liver transplantation. 
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METHODS 
This was a longitudinal, nested cohort study of patients transplanted aged <18 years, who 
were >3 years after initial liver transplant, and continued to be followed up by our service. 
TBK measurements were performed in most patients as part of their transplant 
assessment prior to listing at our institution. Only patients still resident in Queensland at 
the time of this study were able to have post-transplant TBK assessment. Patients who did 
not have pre-transplant TBK measurements were excluded from this study as it precluded 
longitudinal assessment. Participants had their height and weight recorded and their TBK 
measured. This study was approved by the Ethics Committee, equivalent to the 
institutional review board of our institution, of Royal Children’s Hospital. Written consent 
was obtained from parents, or subjects if they were aged >18 years. 
TBK is predominantly intracellular and a fixed proportion occurs as the natural 
isotope 40K, which emits 1.46MeV gamma rays. TBK is measured using a shadow shield 
whole body counter (Accuscan, Canberra Industries, MA, USA) containing three sodium 
iodide crystal scintillation detectors arranged over a scanning bed. Subjects lie supine on 
the scanning bed for two, 20 min measurements (the average of which is taken), while the 
bed moves slowly under the detectors and the gamma rays emitting from the patient’s 40K 
are measured. 
Body Cell Mass (BCM) is calculated from TBK measurements using the following 
equation:  BCM (kg) = (TBK*9.20)/39.1 (12). As BCM is related to body size, 
measurements of BCM need to be adjusted for height in children. This was done 
according to the work of Murphy and Davies where BCM was divided by height raised to 
the power (p) of 2.5 for females and 3 for males (13). BCM/heightp values were compared 
pre- and post-transplant for each patient. Body Mass Index (BMI) was calculated as weight 
(kg)/ height (m) 2. Height, weight, and BMI, age and sex adjusted Z-scores were calculated 
based on World Health Organisation (WHO) Child Growth Standards 2006 and WHO 
reference 2007 charts. 
 Data were analysed to examine the effect of age at transplantation on BCM/heightp 
because nutrition restriction in infancy is recognised to affect epigenetic programming, 
such that those who were underweight as infants are predisposed to developing metabolic 
syndrome, hypertension and diabetes as adults (14, 15). Subjects with height  <10th centile 
(Z-score <-1.29) at pre-transplant TBK assessment were considered to have linear growth 
impairment, and were further examined as our previous data has shown this group to have 
the best growth recovery, but remained shorter and lighter than the rest of the cohort (5). 
The effect of underlying diagnosis was also evaluated as some conditions such as 
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metabolic disorders and Alagille syndrome have potential to affect BCM. Cumulative 
steroid use in the first year after transplant was calculated by adding the daily steroid dose 
for the first 365 days after transplant, then dividing this total by the subject’s weight at the 
end of the first post-transplant year. The duration of regular steroid use, and number of 
subjects still on steroids at the time of post transplant TBK measurement were also noted. 
 Patients who were aged ≥18 years were considered overweight if their BMI ≥25 and 
obese if BMI ≥30. Children aged <18 years were considered overweight using the 
International Obesity Taskforce BMI reference table based on an international survey from 
6 countries, which corresponds approximately to 90th centile for overweight, and 99th 
centile for obese (16). 
Statistical analyses were performed using the SPSS statistical package. Fisher 
exact test was used for categorical data, while Student t test was used to compare the 
means of continuous variables. Multivariate linear regression analyses were then 
performed to assess the relative importance of factors that were significant in univariate 
analysis.  
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RESULTS 
The Queensland Liver Transplant Service (QLTS) commenced in 1985 and was a major 
referral centre for paediatric liver transplantation for Australia, New Zealand and Asia until 
the mid 1990s when other centres developed their own programs. QLTS performed 293 
liver transplants in 249 children aged <18 years between 1985 until the end of 2009. 73% 
(182/249) were still alive at the time of this study (2011-12). 85 of these survivors were 
Australian but only 58 were resident in Queensland at the time of the study, with the rest 
having returned to their homes overseas or in other Australian states.  
 The demographics of participants and non-participants resident in Queensland are 
shown in Table 2.1. There were no differences in age at transplant, Pediatric End-Stage 
Liver Disease (PELD) score, height Z-score at transplant, diagnosis of biliary atresia, or 
survival since transplant between participants and non-participants. Among study 
participants, there were also no differences in these variables between males and females 
(data not shown).  
Height and weight Z-scores were significantly improved after transplant for all 
patients as expected (Table 2.2). No significant change was noted in BMI after transplant, 
which is indicative of proportional changes in height and weight and confirms the limitation 
of BMI as a marker of nutritional state. No differences were noted in height, weight or BMI 
Z-scores between males and females at both pre- and post-transplant assessments. 
BCM/Heightp was significantly reduced after transplantation compared with pre-transplant 
for all subjects. While this reduction was noted in both genders, it was statistically 
significant in males, but not females, even though no differences were noted between 
them in either pre-transplant or post-transplant variables.  
In our laboratory, normative data for BCM/Heightp is available for children over 5 
years of age to allow the calculation of Z-scores using the LMS method (13). BCM/Heightp 
Z-scores could be calculated in only 7 of the 32 patients before transplant and 30 of the 32 
patients after transplant as the remaining patients, 25 pre-transplant and 2 post-transplant, 
were aged <5 years at the time of TBK testing. Using a one-tailed t-test against zero to 
compare to the age-matched population mean, pre-transplant BCM/Heightp was 
significantly reduced,  mean Z-score  -0.50 ±0.52, (p=0.04), and further reduced after 
transplant, mean Z score -0.83 ±1.16, (p<0.001), despite being assessed many years 
later.  This indicates that even though BCM was reduced compared to normal before 
transplant, there was no recovery and instead reduced even further after transplant.  
Subjects with post-transplant BCM/Heightp Z-scores were subdivided into those 
with BCM/Heightp for age <10th centile (Z-score <-1.29), and those with BCM/Heightp ≥10th 
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centile (Table 2.3).  Patients with low BCM had mean post-transplant BCM/Heightp Z-score 
-2.15 (±0.52) compared to Z-score -0.18 (±0.76) for those who were normal. No 
differences were noted in pre- and post-transplant height, weight, and BMI Z-scores, and 
in steroid exposure between the two groups. Patients with low BCM/Heightp, especially 
males, tended to be older at transplant, median 6 years, compared to 2.11 years, but this 
was not significant on univariate analysis. 
Subjects with pre-transplant linear growth impairment were by definition significantly 
shorter, but also lighter prior to transplant than those who were not growth impaired (Table 
2.4). For the total group, there was no difference in age at transplant between those with 
linear growth impairment and those who were not, although growth impaired boys were 
younger at transplant compared to normally grown boys. After transplant, there were no 
significant differences in height and weight Z-scores between groups, indicating good 
recovery in growth impaired children although they still tended to be shorter and lighter. 
BCM/Heightp was reduced after transplant in all subjects and was most marked in those 
with linear growth impairment. Interestingly, normally grown males had reduced 
BCM/Heightp compared to males with linear growth impairment, both before and after 
transplant; however the change in BCM/Heightp was most marked in growth impaired 
males. This effect was not seen in females.  
Some conditions, particularly metabolic diseases such as cystic fibrosis, and 
Alagille syndrome, have the potential to affect body composition. To exclude this as a 
cause for our findings, we analysed children with biliary atresia as a group and compared it 
to children with other diagnoses, which included a mixture of metabolic, autoimmune, and 
idiopathic causes. Children with biliary atresia were significantly younger at transplant, 
median 0.92 (0.38-4.17) years, than those with other diagnoses, 6.68 (1.15-10.92) years, 
p=0.001, but no differences were noted in height, weight and BMI Z-scores pre- or post-
transplant between groups (data not shown). Similar to previous findings, both groups had 
significantly reduced BCM/Heightp after transplant, ΔBCM/Heightp -2.37 ± 2.21 (p<0.001) 
for biliary atresia, and ΔBCM/Heightp -1.23 ± 1.49 (p=0.01) for non biliary atresia.  Again, 
this difference was prominent in males but not females.  
Multiple linear regression analyses were used to examine the effect of gender, 
underlying diagnosis (biliary atresia vs. not biliary atresia), and age at transplantation on 
pre-transplant BCM/Heightp (Table 2.5). Ongoing steroid use instead of underlying 
diagnosis, however, was used in the post-transplant and change in BCM/heightp models 
(Table 2.5). Height at transplant was not included in the model since BCM/Heightp 
calculation corrects for height. Only age at transplant was significantly associated with 
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post-transplant BCM/Heightp (p=0.02), and was almost significant with pre-transplant 
BCM/Heightp (p=0.05). Older children had lower BCM/Heightp at both pre- and post-
transplant assessment than those transplanted at younger ages. Gender, underlying 
diagnosis, and ongoing steroid use were not significant predictors of BCM/Heightp. None 
of the variables examined were significant in predicting change in BCM/heightp 
(ΔBCM/Heightp). 
Only 1 child in this study was by definition considered overweight after transplant 
with BMI Z-score 1.69, just over the 90th centile. This boy, with biliary atresia, was 
significantly growth impaired with height Z-score -2.08, although his weight Z-score was 
0.26. His post transplant BCM/Heightp Z-score -0.06 was on the 47th centile, and was 
normal. Interestingly, his ΔBCM/Heightp, indicating the change between pre- and post-
transplant measurements was -0.76, indicating he lost less BCM after transplant compared 
with most of the other subjects. 
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DISCUSSION 
The recovery from malnutrition, particularly of body composition, after liver transplant is not 
well characterised. As expected, our subjects had reduced BCM compared to normal 
before transplant due to the malnutrition associated with end-stage liver disease. 
Surprisingly however, their long-term post-transplant BCM was further reduced despite 
normalization of height and weight even though some were 15 years post-transplant. 
Since this weight recovery after liver transplant is not due to improved BCM, it is likely that 
increased fat mass is the cause.  
The reason for this long-term post-transplant reduction in BCM is unclear. TBK, 
which measures BCM, the metabolically active component of fat-free mass includes 
muscle and organs, but excludes water and fat. Resolution of portal hypertension 
associated splenomegaly after transplant may hypothetically be a cause of reduced TBK 
after transplant as solid organs are included in the measurement. However, less than half 
our cohort had moderate to severe splenomegaly before transplant, which resolved after 
transplant. Most subjects either had no splenomegaly or no change in spleen size after 
transplant. Additionally, the greatest reduction in post-transplant BCM occurred in a patient 
who had a splenectomy prior to pre-transplant assessment. Resolution of organomegaly 
therefore is not the explanation for post-transplant BCM reduction in our subjects.  
Similar findings have also been noted in adults up to 24 months after liver 
transplantation (6). While this study has longer follow up at median 7.23 years post-
transplant, our conclusions are similar in that ongoing weight recovery after liver transplant 
is likely due to increased fat mass since no recovery of BCM occurred. No other long-term 
body composition data is available after solid organ transplantation, particularly in children. 
Obesity is recognised to be problematic in adults after liver, kidney and stem cell 
transplant (8, 11). Our results suggest that this is also likely to be the case after childhood 
liver transplantation even though the children may not be overtly overweight or obese on 
standard anthropometric measures. Interestingly, increased fat mass and reduced lean 
mass has also been noted in children seven years after hematopoietic stem cell transplant 
using dual energy x-ray absorptiometry scanning (17). 
An alternative explanation may be the “thrifty phenotype” effect proposed by Hales 
and Barker (18). They proposed that fetal under-nutrition permanently affects the body’s 
metabolic responses, predisposing them to subsequent diabetes and obesity once they 
are exposed to adequate nutrition, particularly in adulthood (18). Singhal and Lucas later 
proposed that accelerated postnatal catch up growth was more important (19). Clearly 
fetal and early infancy are important periods when programming of subsequent metabolic 
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responses of the body may occur. However, our findings show that older instead of 
younger age at transplant, was negatively correlated with BCM/Heightp; although the 
degree of change, ∆BCM/Heightp, was not affected. Additionally, adult patients after 
transplantation have also been reported to have poor BCM recovery and increased fat, 
hence the interest in post-transplant sarcopenic obesity (8, 20). While it may be argued 
that prolonged exposure to under nutrition as a result of chronic liver disease in childhood 
is a factor, most adults requiring transplantation have conditions that develop after 
childhood. The reduction in BCM after transplant, therefore, cannot be explained by either 
Barker’s or Lucas’ hypotheses alone although the concept of metabolic re-programming as 
a result of under-nutrition remains possible. 
Immunosuppression, common to all organ transplantation, may have a role in 
affecting both BCM and fat mass. Glucocorticoids are recognised to be important in 
programming the hypothalamic-pituitary axis and it is possible that exposure to high doses 
in the early post-transplant period is important (21). Its effect was proposed in an editorial 
in 2008 discussing whether children after liver transplant were more prone to non-alcoholic 
fatty liver disease (22). Ongoing steroid use has been reported to result in both reduced 
BCM and increased fat mass up to 24 months after liver and kidney transplantation in 
adults (23, 24). A recent study after renal transplantation in children also found reduced fat 
mass at 12 months in those who stopped steroids at 7 days compared to those who 
continued steroids for 12 months (25).  In contrast, our study did not find steroid dose in 
first post-transplant year, duration of steroid therapy, or ongoing steroid use, to predict 
reduced BCM/Htp Z after transplant at long-term follow up. The main difference between 
these studies and ours however is the duration of follow up and it is possible that steroid 
exposure is no longer significant in the long-term as we excluded patients surviving less 
than three years after transplant.  
Our results also show that gender, diagnosis of biliary atresia, and age at transplant 
did not correlate with the degree of change in BCM after transplant. Linear growth 
impairment however was associated with greater reduction in BCM/Heightp after transplant 
on univariate analyses. Linear growth impairment is often used as an indicator of severe 
malnutrition in children, a common problem in solid organ failure. The reduced BCM 
despite good weight recovery, and therefore increased fat mass, all suggest that 
malnutrition may have long lasting effects on metabolic re-programming, regardless of 
age. The changes in malnutrition that may lead to long-term metabolic re-programming 
however are unknown. It is possible that stress or endogenous steroids may be significant 
as stressful life events have been reported to be associated with more rapid weight gain in 
 85 
individuals who become obese (21, 26). DNA methylation, histone modification, and micro 
RNA have all been proposed to be involved in the epigenetic effects of disease and may 
also have a role in metabolic re-programming (27).  
There is a term, “skinny fat”, currently used in popular culture to describe a person 
who is slim, but has little lean muscle and may even have a high fat percentage. This 
expression, while somewhat facetious, actually describes our transplant cohort well. 
Despite normal weight and BMI, these long-term survivors after childhood liver transplant 
have reduced BCM and likely increased fat mass. The implication of reduced BCM and 
increased fat mass after childhood liver transplant is the potential to develop sarcopenic 
obesity, diabetes, and metabolic syndrome with increasing age. Whether this can be 
altered by exercise, particularly resistance training, or by protein and other dietary 
supplementation is unknown. Clearly, further studies on body composition and whether we 
can reverse this reduction in BCM after liver and other solid organ transplantation is 
necessary.  
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Table 2.1: Demographics of potentially eligible participants and non-participants 
 
 Participants 
(n=32) 
Non-participants 
(n=26) 
p-value 
Males 20 (62%) 12 (46%) 0.29 
Age at OLT 2.11  
(0.38-10.92) 
1.92 
(0.14-14.69) 
0.49 
PELD score at OLT 
(mean ± SD) 
13.75 ± 8.77 14.40 ± 14.13 0.74 
Height Z-score at OLT 
(mean ± SD) 
-1.12 ±1.50 -0.92 ± 1.50 0.50 
Survival to date^ 16.36 
(3.44-24.65) 
13.79 
(3.41-27.81) 
0.95 
Diagnoses 
    -Biliary atresia 
    -Metabolic disease 
    -Alagille syndrome 
    -Miscellaneous 
 
19 (59%) 
7 
3 
3 
 
17 (65%) 
4 
2 
3 
 
0.79 
Age at pre-OLT TBK 
 
1.47 
(0.36-10.27) 
-  
Age at post-OLT TBK 
 
10.12 
(4.56-20.77) 
-  
Time pre TBK to OLT 0.24 
(0.02-2.63) 
-  
Time OLT to post TBK 7.23 
(3.28-14.99) 
-  
^to 31st December 2012. Age and time expressed as median (range) years.  
OLT: Orthotopic Liver Transplant; PELD: Pediatric End-Stage Liver Disease score; SD: 
Standard Deviation; TBK: Total Body Potassium measurement 
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Table 2.2: Mean (±SD) pre- and post-transplant anthropometry 
 Total 
(n=32) 
Females 
(n=12) 
Males 
(n=20) 
p-value 
Height Z-scores     
  Pre-transplant -1.12±1.50 -1.40±1.69 -0.95±1.40  0.72 
  Post-transplant -0.41±1.36 -0.57±1.75 -0.31±1.09 0.98 
                   p-value 0.01* 0.06 0.09  
Weight Z-scores     
  Pre-transplant -0.78±1.31 -0.94±1.30 -0.68±1.34 0.52 
  Post-transplant -0.26±1.14 -0.33±1.27 -0.22±1.09 0.95 
                   p-value 0.02* 0.12 0.10  
BMI Z-scores     
  Pre-transplant -0.05±1.12 0.07±1.08 -0.13±1.16 0.80 
  Post-transplant 0.04±0.99 0.17±0.76 -0.04±1.11 0.54 
                   p-value 0.62 0.75 0.72  
BCM / Heightp     
  Pre-transplant 7.10±1.93 6.67±2.27 7.38±1.69 0.78 
  Post-transplant 5.24±0.82 5.55±0.54 5.05±0.91 0.08 
                   p-value <0.001** 0.13 <0.001**  
  Change (Δ) -1.84±1.96 -1.12±2.37 -2.29±1.55 0.42 
*p<0.05, **P<0.005 
BMI: Body Mass Index; BCM/Heightp: Body Cell Mass /Heightp 
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Table 2.3: Comparing subjects with low vs normal post-transplant BCM/Heightp. 
 BCM/Htp <10th 
centile (Z<-1.29) 
(n=10) 
BCM/Htp ≥10th 
centile (Z ≥ -1.29) 
(n=20) 
 p-value 
BCM/Htp Z-score -2.15 ± 0.52 -0.18 ± 0.76 <0.001** 
Males 50% (n=5) 70% (n=14) 0.43 
Age at transplant     
 All 6.00 
(0.61-10.92) 
2.11 
(0.38-7.81) 
0.10 
 Males 7.83  
(1.0-10.3) 
1.60 
(0.38-7.81) 
0.13 
 Females 1.15 
(0.61-10.92) 
2.31 
(0.74-5.12) 
0.54 
p-value 0.32 0.67  
ΔBCM/Htp -1.95±1.58 -1.88±2.06 0.65 
Height Z-score    
 Pre-transplant -1.13 ± 1.25 -1.19 ± 1.68 0.63 
 Post-transplant -0.40 ± 1.34 -0.47 ± 1.45 0.57 
Weight Z-score    
 Pre-transplant -0.80 ± 1.03 -0.86 ± 1.48 0.78 
 Post-transplant -0.19 ± 1.24 -0.44 ± 1.06 0.51 
BMI Z-score    
 Pre-transplant -0.13 ± 0.94 -0.07 ± 1.24 0.64 
 Post-transplant  0.10 ± 0.92 -0.17 ± 0.87 0.71 
Steroid exposure    
Cumulative dose in 1st 
year post-OLT 
(mg/kg) 
83.15 ± 30.90  83.94 ± 18.33 0.91 
Duration steroid use  5.21  
(2.16-7.0) 
5.00 
(2.33-7.20) 
1.00 
Number still on 
steroids at post-OLT 
TBK  
10% (n=1) 15% (n=3) 1.00 
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*p<0.05, **P<0.005. 
Age and time expressed as median (range) years 
Z-scores, ΔBCM/Htp and cumulative steroid dose expressed as mean ± SD 
BCM/Htp: Body Cell Mass / Heightp; BMI: Body Mass Index;  
ΔBCM/ Htp: change in BCM/Htp post-transplant compared with pre-transplant.  
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Table 2.4: Effect of pre-transplant growth impairment on BCM/Heightp 
 Growth Impaired  
Pre-OLT 
(Ht <10th centile) 
n=15 
Normal Growth 
Pre-OLT 
(Ht ≥10th centile) 
n=17 
p-value 
Height Z-scores    
 Pre-transplant -2.34±1.15 -0.04±0.76 <0.001** 
 Post-transplant -0.81±1.51 -0.06±1.14 0.16 
p-value 0.00** 0.95  
Males 53% (n=8) 71% (n=12) 0.47 
Age at OLT (yrs)    
  All 1.55 
(0.38-8.1) 
2.77 
(0.58-10.92) 
 0.10 
  Males 1.13 
(0.38-4.33) 
3.43 
(0.58-10.3) 
0.03* 
  Females 2.05 
(0.61-8.1) 
2.16 
(0.74-10.92) 
0.94 
p-value 0.43 0.79  
Weight Z-scores    
  Pre-transplant -1.74±1.27 0.07±0.54 <0.001** 
  Post-transplant -0.56±1.23 0.01±1.02 0.25 
p-value 0.00** 0.80  
BCM/Heightp    
  Pre-transplant 7.71±1.99 6.53±1.74 0.08 
  Post-transplant 5.42±0.48 5.07±1.01 0.36 
p-value <0.001** 0.01*  
 ∆BCM/Heightp -2.29±2.11  -1.42±1.77 0.07 
Males  
(BCM/Htp) 
   
  Pre-transplant 8.57±1.42 6.51±1.32 0.01* 
  Post-transplant 5.50±0.55 4.74±0.99 0.03* 
p-value 0.00** 0.01*  
 Males ∆BCM/Htp -3.07±1.68 -1.23±2.10 0.02* 
Females    
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(BCM/Htp) 
  Pre-transplant 6.73±2.18 6.58±2.65 0.53 
  Post-transplant 5.33±0.41 5.86±0.58 0.21 
p-value 0.16 0.57  
 Females 
∆BCM/Htp 
-1.40±2.32 -0.72±2.64 0.24 
*p<0.05, **P<0.005 
Age expressed as median (range). Z-scores and BCM/Htp expressed as mean±SD 
OLT: Orthotopic Liver Transplant; Ht: height; BCM/Htp: Body Cell Mass /Heightp;  
ΔBCM/ Htp: change in BCM/Htp post-transplant compared with pre-transplant.  
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Table 2.5. Multivariate linear regression analyses for BCM/Heightp 
Variable Coefficient Standard 
Error 
Beta p-value 
Pre-OLT BCM/Heightp     
Constant 7.64 1.20  0.00 
Gender 0.82 0.66 0.21 0.22 
Age at transplant -0.28 0.14 -0.48 0.05 
Diagnosis BA vs. not BA -0.04 0.91 -0.01 0.96 
Post-OLT BCM/Heightp     
Constant 5.85 0.26  0.00 
Gender -0.46 0.27 -0.28 0.10 
Age at transplant -0.10 0.04 -0.41 0.02* 
Ongoing steroid use 0.16 0.40 0.06 0.70 
Change (Δ) in 
BCM/Heightp 
    
Constant -1.97 0.65  0.00 
Gender -1.17 0.67 -0.30 0.09 
Age at transplant 0.20 0.10 0.33 0.06 
Ongoing steroid use 1.34 0.99 0.23 0.18 
*p<0.05  
Pre-OLT model R2=0.275; Post-OLT model R2= 0.268; Change model R2= 0.229 
BCM: Body cell mass; OLT: Orthotopic liver transplantation; BA: biliary atresia. 
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Specific Aim 3: Bone mineral density 
Ee LC, Noble C, Beale K, Fawcett J, Cleghorn GJ. “Bone mineral density of very long-term 
survivors after childhood liver transplantation” (manuscript in preparation) 
 
ABSTRACT  
Background and Aim: Liver transplantation is recognised to affect bone mineral density 
(BMD). Our aims were to assess BMD in long-term survivors after childhood liver 
transplantation; and examine whether body cell mass (BCM) predicts BMD. 
Methods: Cross-sectional study of patients aged <18 years at transplant, survived >5 
years, still in contact with our centre. Dual-energy absorptiometry (DXA) scan was used to 
measure lumbar spine (LS) and total body (TB) BMD. BCM was calculated from total body 
potassium (TBK) measurements and adjusted for height (BCM/Heightp). Variables 
examined include age at transplant, time from transplant, height, weight, and body mass 
index (BMI) at time of DXA, and where available, post-transplant BCM/Heightp.  
Results: 42 patients, 17 males, had DXA scans. TBK measurements were available in 19 
patients. 64% had biliary atresia. Median age at transplant was 2.22 (range 0.38-14.25) 
years; time after transplant 10.10 (5.01-25.98) years; and age at DXA 14.64 (6.59-38.07) 
years. Mean BMD Z-scores were LS -0.15±1.07, and TB -0.76±1.14, with no gender 
difference noted. Four (10%) patients had reduced LS BMD (Z <-2.0) with ongoing steroid 
use more frequent than in those with normal BMD, 75% (3/4) vs. 21% (8/38), p=0.049. 
Age at transplant, time from transplant, height or weight at DXA, and BCM/heightp did not 
predict lumbar spine BMD. Pathologic fractures occurred within 18 months of transplant.  
Conclusion: Long-term survivors after childhood liver transplant normalise their BMD but 
remain at risk of osteopenia, which is not predicted by BCM, especially if they remain on 
steroids. 
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INTRODUCTION  
Children with end-stage liver disease are susceptible to osteopenia and fractures, 
presumably as a result of malnutrition associated with chronic liver disease1. Normalization 
of liver function and resolution of malnutrition after transplant would be expected to 
ameliorate this risk. This presumption, unfortunately, is not corroborated by multiple 
reports of increased incidence of fractures and osteopenia in adult liver transplant 
survivors even at long-term review2, 3. Reduced bone mineral density (BMD) within the first 
3-4 months after transplantation has been reported in both adults and children4, 5.  
Longitudinal studies in adults show improvement in BMD after this time, with ongoing 
recovery up to 8 years post-transplant5, 6. Similarly, children were also reported to increase 
BMD beyond 4 months of transplant, although follow up was only to 24 months7, 8. 
 There is limited data on long-term BMD after transplantation in childhood, with the 
longest follow up at 12 years post-transplant. Normalization of BMD was reported by all, 
with mean lumbar spine BMD Z-scores between -0.27 to -0.66 at follow up, but conflicting 
data on predictors of reduced BMD. Guthery et al, in the largest study to date, found 
significant correlation with height and weight Z-scores, time after transplant, and steroid 
exposure in the year preceding dual-energy absorptiometry (DXA) assessment9. In 
contrast, three subsequent smaller studies found no correlation with ongoing steroid use10-
12. Time after transplant was important in all except one study. This study only included 
patients >4 years after transplant and had the longest follow up at mean 12 years, but only 
had 15 patients13. Age at transplant was reported to be important where those 
transplanted aged >10 yr were more likely to have reduced BMD10, 11. Body mass index 
(BMI) was also noted to be an important predictor of low BMD in a Canadian study of 52 
children10.  
 Lean mass has been reported to predict BMD in normal children, especially in 
males14, 15. An interesting report in adult patients found significant correlation between lean 
mass and BMD, even though 62% of this cohort was overweight or obese by BMI 
definition16. In contrast, a small study of nine infants found no improvement in fat or lean 
mass despite improvement in BMD 6 months after liver transplant17. No other data 
describing the effect of body composition on BMD after liver transplantation in children is 
available.  
Body composition analysis is recognised to be a better indicator of nutritional state 
than anthropometry, subjective global assessment, and skin fold measurements as these 
underestimate the degree of malnutrition in both children and adults with liver disease18, 19. 
Of the various body composition techniques available, total body potassium (TBK) 
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assessment is considered the “gold standard” in measuring body cell mass (BCM), the 
metabolically active component of fat free mass, because it is not affected by fluid shifts, 
and is therefore an accurate, reliable measure of nutritional state20. In contrast, DXA 
includes extracellular fluid in its assessment of lean mass so is influenced by fluid 
perturbations21, 22. While the relationship of height, weight, BMI and lean mass (by DXA) to 
BMD have been described, no studies on effect of BCM on BMD are reported.  
  The main limitation of currently published paediatric studies however, is the 
inclusion of patients within the first two years of transplant when they are still susceptible 
to post-transplant complications, and recovering from malnutrition associated with end-
stage liver failure. The duration of follow up is also medium rather than truly long-term. 
More studies on long-term BMD and further investigation as to significant predictors of 
BMD are clearly required.  The aims of this study therefore were to assess BMD of very 
long-term survivors after liver transplantation in childhood, and to assess the impact of 
nutritional status, especially BCM, on BMD.   
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METHODS 
Patients were considered long-term survivors if they survived >5 years after initial liver 
transplantation. Those who were transplanted aged <18 years, and survived >5 years after 
transplant, were eligible to participate. Study participation was restricted to subjects 
resident in Queensland at the time of the study due to difficulty in recruiting overseas and 
interstate patients. Survival from transplant was calculated to 31st December 2013. This 
study was approved by the Ethics Committee, the institutional review board equivalent, of 
the Royal Children’s Hospital, where paediatric Queensland Liver Transplant Service 
(QLTS) is based.  
DXA (Lunar Prodigy, GE Healthcare, Madison, WI, USA) was used to assess BMD, 
which was then compared to an age matched reference population to obtain Z-scores. 
Reference populations were the Lunar Paediatric software data for patients aged <20 
years, and the Geelong Osteoporosis Study for adults23.  The most recent DXA result was 
used in those who had multiple scans. BMD measurements of total body (TB) and lumbar 
spine (LS) were performed in all patients aged <20 years. Patients aged ≥20 years had LS 
and femoral neck assessment but not TB. These patients had both Z- and T-scores 
reported but only Z-scores were used to compare LS BMD between patients since T-
scores are only appropriate for adults. Bone age was determined from a left wrist 
radiograph according to Greulich and Pyle in pre-pubertal children24. Height and weight 
were measured at transplant and again on the day of testing or as close as possible to 
these dates. Body Mass Index (BMI) was calculated using the formula BMI= weight (kg)/ 
height2 (m). Height, weight, and BMI age and sex adjusted Z-scores were calculated 
based on World Health Organisation (WHO) Child Growth Standards 2006 and WHO 
reference 2007 charts. BMD Z-score ≤-2.0 was considered reduced by definition according 
to the International Society for Clinical Densitometry25. 
Total body potassium (TBK) is predominantly intracellular and a fixed proportion 
occurs as the natural isotope 40K, which emits 1.46MeV gamma rays. TBK is measured 
using a shadow shield whole body counter (Accuscan, Canberra Industries, MA, USA) 
containing three sodium iodide crystal scintillation detectors arranged over a scanning bed. 
Subjects lie supine on the scanning bed for two, 20 min measurements (the average of 
which is taken), while the bed moves slowly under the detectors and the gamma rays 
emitting from the patient’s 40K are measured. Body Cell Mass (BCM) is calculated from 
TBK measurements using the following equation:  BCM (kg) = (TBK*9.20)/39.126. As BCM 
is related to body size, measurements of BCM need to be adjusted for height in children. 
This is done according to the work of Murphy and Davies where BCM was divided by 
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height raised to the power (p) of 2.5 for females and 3 for males27. In our laboratory, 
normative data for BCM/Heightp is available for children over 5 years of age to allow the 
calculation of Z-scores using the LMS method27. The longitudinal change in BCM/Heightp 
from pre-transplant to post-transplant, ΔBCM/Htp, was also calculated.  
Data was further analysed to examine the effect of age at transplant, time since 
transplant, height, weight and BMI at time of DXA, and BCM/Heightp on BMD. Two age 
limits were examined, those >10 years, and those ≤2 years at transplant. Children aged 
>10 years were reported to have reduced BMD at long-term review, and we were 
interested in the effect of transplantation in infancy10, 11. Time since transplant was divided 
into 5 year intervals, viz. >5 years to ≤10 years, >10years to ≤15 years, >15years to ≤20 
years, and >20 years to examine the effect of duration from transplant on BMD. Height, 
weight, BMI and BCM/Heightp Z-score <10th centile (Z<-1.29) were considered significantly 
reduced for age.  
Descriptive data was described as median with ranges. Z-scores were expressed 
as mean ± standard deviation (SD). Student t-test was used to compare the means of 
continuous data. Fisher exact test was used to compare categorical data. Results were 
considered statistically significant if p <0.05. Statistical analyses were performed using 
GraphPad software available on the web (www.graphpad.com/quickcalcs/). 
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RESULTS 
There were 285 liver transplants performed in 242 children between 1985 to 31st 
December 2008, of which 195 (81%) patients survived at least 5 years after initial liver 
transplantation.  Only 33% (64/195) of these survivors were Queensland residents, while 
the rest were from overseas or other states.  Forty two patients agreed to participate of 
which 38 were Queensland residents, while the remaining four patients were visiting from 
their home states but agreed to participate. Demographics of participants and Queensland 
non-participants are shown in Table 1. No differences were noted between participants 
and non-participants. Biliary atresia was the commonest reason for transplantation in all 
patients.  
LS Z-scores were available in all patients and TB Z-scores in 32/42 patients. Mean 
BMD Z-scores were in the normal range for both LS and TB, although LS BMD Z-score -
0.15 was better than TB BMD Z-score -0.76 (Table 3.1). Mean Z-scores for anthropometric 
measurements at the time of DXA were height -0.34 ± 1.34, weight -0.06 ± 1.17, and BMI 
0.21 ± 0.93. No gender difference was noted in these anthropometric measurements or in 
BMD Z-scores (data not shown).  
Four patients, 10%, were noted to have reduced lumbar spine BMD, with 
comparisons between subjects with reduced and normal LS BMD shown in Table 3.2. 
Among those with reduced BMD, bone age was normal in two, delayed in one, and not 
performed in one patient as she was >20 years at the time of DXA. Ongoing steroid use 
was significantly more common in these patients, 75%, compared to those with normal LS 
BMD, 21%, p=0.049. These patients were also older at transplant, shorter at DXA 
assessment, and had reduced BCM/Heightp but these variables were not significantly 
different from patients with normal BMD.  
The girl with delayed bone age and reduced LS BMD had fractures of her 
vertebrae, ribs, forearm, and femur, not associated with trauma, prior to transplant. She 
started pamidronate therapy pre-transplant, and remained on it for 4 years post-transplant 
despite improvement in BMD on serial DXA as she was steroid dependent and sustained 
more fractures, forearm and vertebral, within 12 months of transplant. The boy with 
reduced LS BMD and normal bone age, has cystic fibrosis, sustained a fractured forearm 
pre-transplant, and two forearm fractures within 18 months post-transplant from minimal 
trauma. He was not on steroids prior to transplant, nor at the time of his DXA. Four post-
transplant fractures were sustained by three patients with normal BMD, all from significant 
trauma, and occurred at least 2 years after transplant. None were on steroids at the time of 
fracture. The overall post-transplant fracture incidence was 12% (5/42), but this is an over-
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estimate since it includes traumatic fractures. If we exclude these, the incidence of post-
transplant pathologic fracture was 5% (2/42), with all occurring within 18 months of 
transplant.  
The effect of age at transplantation, both ≤2 years, or >10 years were examined 
(Table 3.3). While age at transplant, and therefore age at DXA were significantly different 
as expected, the duration of time since transplant was similar between groups. No 
difference was noted in LS BMD Z-scores between the different age groups. There was 
also no difference in TB BMD Z-score between those aged ≤2 years vs. >2 years at 
transplant; no results were available for those aged >10 years after transplant as they 
were aged >20 years at time of DXA. Children transplanted aged ≤2 years had significantly 
better height Z-score at time of DXA, but no differences noted in other anthropometric 
measures between groups.  
The effect of time since transplantation is shown in Table 3.4. Time post-transplant 
and age at DXA were significantly different between the groups as expected, but no 
differences noted in other variables. TB measurements were not available in those >20 
years post-transplant since they were adults. No differences were noted in BMD Z-scores 
for LS or TB between groups. The percentage of patients still on steroids was similar for all 
time intervals despite some being >20 years after transplant.  
No difference in BMD was noted between growth impaired (height <10th centile), 
and normally grown patients with mean LS BMD Z-score -0.66±1.12 and 0.03±0.97 
respectively (p=0.32). Similarly no difference was found in under-weight compared to 
normal weight patients with mean LS BMD Z-score -0.73±0.85 vs. 0.00±1.03 respectively, 
p=0.09. Only one patient had BMI <10th centile; he was also growth impaired and 
underweight but had normal BMD at both LS (Z-score 0.1) and TB (Z-score -0.2).  
TBK measurements were available in 19 patients. Patients were divided into those 
with low i.e. <10th centile, or normal BCM/Heightp (Table 3.5). No difference was noted in 
the degree of change, ΔBCM/Heightp, from pre- to post-transplant measurement. While 
those with low post-transplant BCM/Heightp tended to have lower LS and TB BMD 
compared to those with normal BCM/Heightp this was not statistically significant. No 
differences were noted in age at transplant, height Z-score at transplant, time from 
transplant or post-transplant anthropometry between the two groups. 
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DISCUSSION 
Our results show long-term survivors after childhood liver transplantation to normalise LS 
BMD, reaching the 44th centile, Z -0.15, 10 years after transplant. These results are better 
than previously reported and also has the longest follow up with some patients >20 years 
post-transplant. Despite this encouraging result, 10% have reduced LS BMD, although this 
prevalence is similar to previous reports of 6-15%9-11. Ongoing steroid use was 
significantly associated with reduced BMD in our cohort. The proportion of patients 
remaining on steroid therapy was unchanged in our cohort at varying time intervals post 
transplant, including those who survived >20 years. While no significant differences in LS 
BMD overall were noted, the association of ongoing steroid use on BMD prompts review of 
their management as to the feasibility of discontinuing steroids. Early steroid 
discontinuation and steroid free regimes should be considered for future patients to 
preserve normal BMD. Interestingly, while steroid use affects BMD in adults, the effect of 
long-term low dose therapy in children remains controversial as other reports have found 
no effect on BMD28.  
 Calcineurin inhibitors, which are almost universally used after transplant, have been 
reported in vitro to inhibit osteoclast formation and bone resorption, and in vivo to cause 
bone loss from increased bone resorption29. Transplanted patients are therefore at 
theoretical risk of drug induced osteopenia from both steroid and calcineurin inhibitor 
therapy. Epidemiologic studies however have not established an association between 
calcineurin inhibitor therapy and fracture risk30. It would be difficult to elucidate the relative 
effects of one medication over the other as well as underlying disease on BMD and 
fractures in the immediate post transplant period when fracture risk is greatest31. 
The relevance of reduced BMD in predicting fractures in children is not as well 
defined as in adults. The overall post-transplant fracture incidence in our cohort was 12%, 
but included those resulting from trauma in normal patients. Interestingly, fractures 
sustained by patients with reduced BMD occurred within the first 18 months post-
transplant, with no further fractures beyond this time despite persistently reduced BMD 5-
15 years after transplant. In contrast, fractures in normal BMD patients occurred many 
years later and were not associated with steroid therapy. While ongoing steroid use was 
associated with reduced BMD, it did not predict fractures, which mainly occurred in the 
early post-transplant years. This implies other factors, such as pre-transplant malnutrition, 
may be more significant in predicting pathologic fractures after transplant. 
Height is often used as an indicator of chronic malnutrition even though body 
composition assessment is recognised to be more accurate than anthropometry in 
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assessing nutritional state19. Lean mass as measured by DXA has been reported to 
correlate with BMD in children and adults15, 16. In our cohort, patients with reduced BMD 
were shorter at the time of DXA but not at transplant, and had reduced BCM/heightp 
compared to normal BMD patients, although both variables were not significantly different 
between groups. In contrast to previous reports, we did not find BCM, measured by TBK 
instead of lean mass by DXA, to predict BMD. Technical aspects between these two 
methods of body composition may be the reason for this as DXA assessment of lean mass 
excludes fat and bone, whereas BCM only assesses the metabolically active component of 
fat free mass and excludes fat, bone and extracellular fluid. Sample size may also be a 
cause for this lack of correlation as TBK measurements were only available in 19 patients. 
The effect of height is recognised to affect both DXA and BCM even though correction for 
height was done with BCM, and to a certain extent with bone age correction for DXA.  
The lack of correlation with weight and BMI with BMD is not surprising as our 
patients were many years post-transplant and had normalized both parameters at the time 
of testing. The correlation of BMI with BMD as reported in adult patients is likely due to its 
use as a marker of malnutrition or obesity. There remains controversy as to whether 
obesity results in increased BMD, particularly in children32. It is likely however that BCM or 
fat free mass, as a marker of nutritional status will be a better marker for BMD than BMI, 
especially in the pre-transplant or early post-transplant period when malnutrition is 
significant. Its utility in long-term patients who are expected to have recovered from 
malnutrition is less clear.  
Time from transplant did not predict BMD in our cohort unlike previous reports 
which included patients within the first two years of transplant. Longitudinal studies in 
adults with interval DXA scanning noted most rapid improvement in BMD within the first 
two years of transplant, with ongoing recovery up to 8 years later but at a slower rate5, 6. 
Since all our patients were >5 years post-transplant, little effect of timing is expected. Age 
at transplant also did not correlate with BMD in our cohort, similar to previous reports. The 
longitudinal study which found age >10 years to be associated with reduced BMD, also 
reported reduced height, weight, and BMD Z-scores after transplant in their cohort11. This 
suggests persistence of malnutrition or the effect of post-transplant medication, as its 
findings are contrary to current published data showing long-term height and weight 
recovery in children after transplant33.  
Our results show very long-term survivors after childhood liver transplantation can 
expect normal BMD but remain susceptible to osteopenia if they remain on steroid 
therapy. Early steroid discontinuation or steroid free regimes of immunosuppression 
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should be considered to ensure normalization of BMD. Pathological fractures in children 
however only occurred within the first 18 months of transplant, with no further fractures 
despite persistently reduced BMD. Age at transplant and time of transplant did not predict 
BMD. Nutritional state as indicated by BCM/Heightp, height, weight and BMI also did not 
predict BMD but this may be because our cohort was generally well nourished since they 
were many years after transplant. Further investigation on the role on BCM and 
longitudinal studies in children after transplant are indicated to better define the long-term 
effects of malnutrition on BMD.  
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Table 3.1: Demographics of Participants vs. non-Participants resident in Queensland 
 Participants 
n=42 
Non-Participants 
n=26 
p-value 
Males 40% (n=17) 58% (n=15) 0.21 
Biliary atresia diagnosis 64% (n=27) 65% (n=17) 1.00 
Age at OLT 2.22  
(0.38-14.25) 
1.60  
(0.14-10.32) 
0.63 
PELD score at OLT 16.50 ± 12.51 16.80 ± 10.98 0.54 
Height Z-score at OLT -1.13 ± 1.52 -1.04 ± 1.45 0.85 
Weight Z-score at OLT -0.86 ± 1.31 -0.86 ± 1.22 0.68 
Survival since OLT† 18.51  
(6.05-28.81) 
16.27  
(6.87-25.14) 
0.07 
Age at DXA 14.64  
(6.59-38.07) 
-  
Time from OLT to DXA 10.10  
(5.01-25.98) 
-  
LS BMD Z-score -0.15 ± 1.07 -  
TB BMD Z-score -0.76 ± 1.14 -  
† Survival calculated to 31st December 2013. 
Age and time expressed as median (range) years; Z-scores expressed as mean ± SD 
OLT: orthotopic liver transplant; DXA: dual energy X-ray absorptiometry 
LS BMD Z: lumbar spine bone mineral density Z-score: TB BMD Z: total body bone 
mineral density Z-score. 
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Table 3.2: Comparing subjects with reduced and normal LS BMD 
 Reduced LS BMD 
(Z-score ≤-2.0) 
(n=4) 
Normal LS BMD 
(Z-score >2.0) 
(n=38) 
p-value 
LS BMD Z-score -2.25 ± 0.21 0.07 ± 0.86 0.02* 
TB BMD Z-score -1.95 ± 0.45 -0.58 ± 1.10 0.14 
Males 25% (n=1) 42% (n=16) 0.64 
Height Z-score at OLT -1.22 ± 0.75 -1.12 ± 1.60 0.37 
Weight Z-score at OLT -0.30 ± 0.73 -0.92 ± 1.35 0.95 
Age at OLT 7.27 
(0.65-9.73) 
2.08 
(0.38-14.25) 
0.97 
Age at DXA 14.73 
(13.12-20.62) 
14.64 
(5.72-25.98) 
0.39 
Time post OLT 10.49 
(5.01-15.52) 
10.10 
(5.72-25.98) 
0.08 
Height Z-score at DXA -2.08 ± 1.58 -0.15 ± 1.19 0.27 
Weight Z-score at DXA -0.75 ± 1.54 0.02 ± 1.12 0.44 
BMI Z-score at DXA 0.31 ± 0.85 0.20 ± 0.95 0.15 
BCM/Htp Z-score -2.04 ± 0.76 -0.80 ± 1.25 0.58 
Ongoing steroid use 75% (n=3) 21% (n=8) 0.049* 
Number of patients with 
post-OLT fractures 
50% (n=2) 8% (n=3) 0.07 
*p<0.05 
Age and time expressed as median (range) years; Z-scores expressed as mean ± SD 
LS BMD Z: lumbar spine bone mineral density Z-score; TB BMD Z: total body bone 
mineral density Z-score; OLT: orthotopic liver transplant; DXA: dual energy X-ray 
absorptiometry; BCM/HtP Z: body cell mass /heightp Z-score 
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Table 3.3: Effect of age at transplant on BMD 
 
 OLT ≤2 yr 
(n=19) 
OLT >2 yr 
(n=23) 
p 
value 
OLT ≤10 yr 
(n=36) 
OLT >10 yr 
(n=6) 
p 
value 
Age at OLT 0.76 
(0.38-1.70) 
6.68 
(2.05-14.25) 
0.00** 1.62 
(0.38-9.73) 
13.42 
(10.00-14.25) 
0.00** 
Age at DXA 10.80 
(6.59-26.81) 
18.14 
(8.81-38.07) 
0.03* 13.28 
(6.59-26.81) 
26.36 
(21.89-38.07) 
0.02* 
Time post-
OLT 
9.78 
(5.97-25.98) 
10.90 
(5.01-24.66) 
0.94 9.55 
(5.01-25.98) 
13.76 
(9.57-24.66) 
0.56 
LS BMD Z 0.14 ± 1.04 -0.33 ± 0.97 0.20 -0.13 ± 1.08 -0.01 ± 0.48 0.26 
TB BMD Z -0.85 ± 1.28 -0.65 ± 0.98 0.39 -0.76 ± 1.14 NA - 
Ht Z at DXA 0.19 ± 1.09 -0.75 ± 1.39 0.01** -0.37 ± 1.44 -0.16 ± 0.42 0.51 
Wt Z at DXA 0.04 ± 0.83 -0.14 ± 1.39 0.62 -0.10 ± 1.22 0.20 ± 0.87 0.99 
BMI Z at 
DXA 
0.14 ± 0.83 0.27 ± 1.03 0.38 0.22 ± 0.94 0.14 ± 0.99 0.64 
* p<0.05, **p<0.005 
Age and time expressed as median (range) years; Z-scores expressed as mean ± SD 
BMD: bone mineral density; OLT: orthotopic liver transplant; yrs: years; DXA: dual energy 
X-ray absorptiometry; LS BMD Z: lumbar spine bone mineral density Z-score; TB: total 
body bone mineral density Z-score; NA: Not available; Ht: height; Wt: weight: BMI: body 
mass index 
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Table 3.4: Time (in years) from transplant on BMD 
 
 
>5 to ≤10 yr 
(n=21) 
>10 to ≤15 yr 
(n=9) 
>15 to ≤20 yr 
(n=7) 
>20 yr 
(n=4) 
Time post-OLT 7.29 
(5.01-9.85) 
12.05 
(10.90-14.35) 
16.01 
(15.48-18.53) 
24.19 
(22.95-25.98) 
Age at OLT 2.05 
(0.62-14.25) 
1.55 
(0.38-10.00) 
2.53 
(0.65-13.43) 
7.12 
(0.62-13.52) 
Ht Z at OLT -1.29 ± 1.83 -0.68 ± 0.98 -1.26 ± 0.84 -0.65 ± 2.20 
Age at DXA 9.90 
(6.59-21.89) 
14.92 
(13.68-22.05) 
19.99 
(16.16-28.92) 
32.02 
(23.57-38.07) 
LS BMD Z -0.02 ± 1.17 -0.26 ± 1.01 -0.36± 1.18 -0.13 ± 0.71 
TB BMD Z -0.89 ± 1.28 -0.54 ± 0.95 -0.55 ± 1.10 NA 
Ht Z at DXA -0.44 ± 1.40 -0.08 ± 1.04 -0.67 ± 1.08 0.67 ± 1.41 
Wt Z at DXA -0.05 ± 1.40 0.16 ± 0.69 -0.39 ± 0.79 0.27 ± 1.26 
BMI Z at DXA 0.25 ± 1.02 0.31 ± 1.00 -0.15± 0.67 0.32 ± 1.01 
Still on steroids 29% (n=6) 22% (n=2) 29% (n=2) 25% (n=1) 
Age and time expressed as median (range) years; Z scores expressed as mean ± SD 
BMD: bone mineral density; Yr: years; OLT: orthotopic liver transplant; Ht: height; LS BMD 
Z: lumbar spine bone mineral density Z-score; TB BMD Z: total body bone mineral density 
Z-score; Wt: weight; BMI: body mass index 
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Table 3.5: Effect of BCM on BMD 
  Low  
BCM/Heightp  
(Z <-1.29) 
(n=8) 
Normal 
BCM/Heightp  
(Z ≥-1.29) 
(n=11) 
p-value 
BCM/Heightp Z -2.09 ± 0.57 -0.08 ± 0.85 0.0046** 
ΔBCM/Heightp  -1.98 ± 1.74 -1.61 ± 2.35 0.35 
Age at OLT 2.67 
(0.62-10.00) 
2.05 
(0.38-6.68) 
0.53 
Time since OLT  6.24 
(5.01-13.77) 
9.32 
(7.16-16.15) 
0.23 
Height Z at OLT -1.31 ± 1.36 -1.86 ± 2.03 0.38 
LS BMD Z -0.34 ± 1.06 0.09 ± 0.87 0.34 
TB BMD Z -1.00 ± 1.00 0.06 ± 0.62 0.14 
Height Z at DXA -0.62 ± 1.62 -0.23± 1.77  0.77 
Weight Z at DXA 0.04 ± 1.61 -0.37 ± 1.33 0.64 
BMI Z at DXA 0.56 ± 1.35 -0.19 ± 0.74 0.27 
*p<0.05, **p<0.005 
Age and time expressed as median (range) years. Z-scores expressed as mean ± SD. 
BCM: body cell mass; BMD: bone mineral density; ΔBCM/Heightp: Change from pre-
transplant to post-transplant BCM/Heightp; OLT: orthotopic liver transplant; LS: lumbar 
spine; TB: total body; DXA: dual energy X-ray absorptiometry; BMI: body mass index 
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Specific Aim 4: Cognitive function and academic performance 
Ee LC, Lloyd O, Beale K, Fawcett J, Cleghorn GJ. “Academic potential and cognitive 
functioning of long-term survivors after childhood liver transplantation” Pediatric 
Transplantation 2014; 18: 272-279.  
 
 
ABSTRACT  
This cross sectional study assessed intellect, cognition, academic function, behaviour, and 
emotional health of long-term survivors after childhood liver transplantation. Eligible 
children were >5 years post transplant, still attending school, and resident in Queensland. 
Hearing and neurocognitive testing were performed on 13 transplanted children and 6 
siblings including 2 twin pairs where one was transplanted and the other not. Median age 
at testing was 13.08 (range 6.52-16.99) years; time elapsed after transplant 10.89 (range 
5.16-16.37) years; and age at transplant 1.15 (range 0.38-10.00) years. Mean full scale 
intelligence quotient (IQ) was 97 (81-117) for transplanted children and 105 (87-130) for 
siblings. No difficulties were identified in intellect, cognition, academic function, and 
memory and learning in transplanted children or their siblings, although both groups had 
reduced mathematical ability compared to normal. Transplanted patients had difficulties in 
executive functioning, particularly in self regulation, planning and organisation, problem 
solving, and visual scanning. 31% (4/13) of transplanted patients, and no siblings, scored 
in the clinical range for ADHD.  Emotional difficulties were noted in transplanted patients 
but were not different from their siblings. Long-term liver transplant survivors exhibit 
difficulties in executive function and are more likely to have ADHD despite relatively intact 
intellect and cognition.   
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INTRODUCTION 
Liver transplantation is now the treatment of choice for many chronic childhood liver 
diseases with high rates of long-term survival (1). Outcomes after transplantation may 
ultimately be judged on the quality of life restored, incorporating both survival and quality 
of time survived (2). Cognitive functioning, academic ability, behaviour and psychosocial 
function in these survivors will all impact on their quality of life and ability to function within 
society.  
Children with end-stage liver disease are vulnerable to cognitive deficits and have 
been reported to have lower performance intelligence quotient (IQ) compared to age-
matched children with cystic fibrosis; with primary diagnosis, age of onset, duration and 
severity of disease all impacting on their performance (3). Paediatric liver transplant 
survivors as a group have been reported to have lower IQ than their peers in several 
studies with follow up times up to 10 years post transplant (4-7). IQ alone, however, is not 
a good predictor of school performance and overall outcome, with poor correlation 
between intellectual functioning (IQ) and academic outcome in children after liver 
transplantation (4). IQ scores also fail to describe subtle cognitive deficits and more 
focused neuropsychological testing is necessary to provide information on specific and 
subtle cognitive deficits (7). Stewart and her collaborators from Dallas in their seminal work 
from the early 1990s identified that these children may have subtle cognitive impairments 
despite relatively normal, albeit in the lower range, intellectual functioning (4, 8, 9).  
There are methodological concerns with many of these outcome studies including 
small sample size, variation in the types of tests used, and a general lack of long-term data 
(7, 10, 11). Additionally, the timing of assessment and age at testing varies significantly, 
making comparisons between centres difficult, which may contribute to conflicting and 
confusing results. These contrasting findings and lack of specific rather than gross overall 
outcomes call for further studies examining long-term cognitive and academic functioning 
of patients who have undergone liver transplantation in childhood. 
The aims of our study therefore were to assess cognitive and academic function, 
general behaviour, and emotional health of long-term survivors after liver transplantation in 
childhood. In this study, siblings will be used as controls rather than those with other 
chronic illness as siblings are a better indicator of potential within individual family context 
and are also subject to the same environmental factors.  
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 METHODS 
The Queensland Liver Transplant Service (QLTS) commenced in 1985 and was a major 
referral centre for paediatric liver transplantation for Australia, New Zealand and Asia until 
the mid 1990s when other centres developed their own programs. Patients surviving ≥5 
years after initial transplant were considered long-term survivors. Long-term survivors who 
were being followed by QLTS, and were attending school (i.e. aged 6-18 years) were 
potentially eligible to participate in this study. The state of Queensland covers a 
geographic area of 1.72 million square kilometres, so regular review in Brisbane, the state 
capital, where QLTS is based is difficult for those living remotely and for inter-state 
patients. This study was restricted to those currently resident in Queensland and mainly 
Brisbane, due to difficulty in getting regional and out of state patients tested. Only patients 
reviewed in Brisbane during the study time frame (2006-2007) were recruited as 
neuropsychological assessment was only available in Brisbane. This study was approved 
by the Ethics Committee of the Royal Children’s Hospital, Brisbane. 
Hearing assessment was performed by an audiologist prior to psychometric testing 
to ensure that hearing loss did not impact on their psychometric test performance. Hearing 
tests performed included pure tone audiometry, tympanometry and transient evoked 
otoacoustic emissions testing.  
Standardised psychometric assessment was performed by the same 
neuropsychologist (OL). Tests included: 
• Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV) (12), 
which assesses intellectual functioning in children, aged 6-17 years of age. It 
yields an overall IQ index score as well as four index scores for Verbal 
Comprehension (verbal cognitive functioning), Perceptual Reasoning (nonverbal 
cognitive functioning), Working Memory, and Speed of Information Processing, 
as composite scores based on ten individual subsets in these domains.  
• Wechsler Individual Achievement Test – Second Edition (WIAT-II) – 
Abbreviated (13) was used as a screen of academic functioning. The 
abbreviated form consists of three subtests, assessing reading, mathematical 
achievement, and spelling. 
• Wide Range Assessment of Memory and Learning – Second Edition 
(WRAML-2) (14) measures verbal and nonverbal learning and memory in 
children and adults aged 5-85 years. The Story Memory, Verbal Learning, 
Design Memory, and Picture Memory subtests were administered.  
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• Rey-Osterrieth Complex Figure Test (RCFT) (15). The Rey Figure is a 
measure of visual-perceptual functioning (copy trial) and visual memory (recall 
and recognition trials).  
• Several subtests from the Delis-Kaplan Executive Functioning System 
(DKEFS) were administered as measures of executive functioning (16-18):   
o Trail Making Test assesses attention control and cognitive flexibility  
o Verbal Fluency measures verbal generativity and cognitive flexibility 
o Colour-Word Interference Test assesses inhibition/impulse control 
o Tower Test assesses planning and goal setting. 
• The Behaviour Rating Inventory of Executive Functioning (BRIEF) parent 
form measures parental perceptions of a child’s executive functioning in 
everyday life (19, 20).  
• The Conners Parent Rating Scale-Revised is a measure of a child’s 
behavioural functioning, particularly in relation to attention and hyperactivity (21). 
• The Child Behaviour Check List (CBCL) is a parent-completed measure of a 
child’s emotional and behavioural functioning (22). 
 
All results were normalised for age and presented as mean ± SD. Transplanted 
patients were compared to sibling controls and both compared to population norms. 
Screening for violations of statistical assumptions was conducted. All non-categorical data 
were found to be normally distributed. As such, parametric tests were able to be used to 
analyse the data. Student’s t test was also used to obtain p values although it is 
acknowledged that interpretation of these results is limited by low subject numbers 
Difference of means and 95% confidence intervals were used to compare mean test 
results between transplanted patients and controls. The Fisher exact test was used to 
compare categorical variables. 
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RESULTS 
The Queensland Liver Transplant Service (QLTS) performed 273 liver transplants in 231 
children aged <18 years between 1985 until the end of 2004. 76% (176/213) survived at 
least 5 years after initial transplant although a further 17 patients died after that time. Only 
61 of these long-term survivors were Australian residents, of which 38 were identified to 
live in Queensland. Among the Queensland patients, 29 were attending school when this 
study was conducted.  
There were 13 transplant survivors and 6 siblings who consented to participate in 
this study. This cohort included 2 sets of twins where one was transplanted and the other 
not. The twins included a transplanted male and his twin sister, and a transplanted female 
and her twin sister. There were 6 boys and 7 girls in the transplanted group while all 6 
siblings were female. Median age at testing was 13.08 (range 6.52-16.99) years for 
transplanted children and 10.99 (range 8.76-14.99) years for controls, which was not 
significantly different (p=0.42). The median time after transplant was 10.89 (range 5.16-
16.37) years, and median age at transplant was 1.15 (range 0.38-10.00) years in 
participants. 
There were 16 potentially eligible children (survived >5 years post transplant, 
attending school, and resident in Queensland) who did not participate in this study. The 
demographics of our subjects and non-participants are shown in Table 4.1. There were no 
differences in gender, age at transplant, PELD score, height Z scores at transplant, 
diagnosis of biliary atresia, transplant era, or time after transplant when compared with 
those participating in the study. Time after transplant was calculated to the date of testing 
for subjects. For non-participants, time after transplant was calculated to Jan 25, 2007, 
which was the median date of testing. More participants were on cyclosporine while more 
non-participants were on tacrolimus at the time of this study.  
All children had their hearing tested prior to psychometric assessment. No child had 
sensorineural hearing loss and all had normal transient evoked otoacoustic emissions, 
indicating normal outer hair cell function despite exposure to ototoxins. Two transplanted 
children had mild conductive hearing loss, one with mild-moderate conductive loss and the 
other with Eustachian tube dysfunction. None had hearing impairment that was significant 
enough to preclude or affect psychometric testing. 
On the WISC-IV testing, no significant difference was found in full scale IQ between 
transplanted and control patients, with mean IQ 97 (range 81-117) vs. 105 (range 87-130) 
respectively (Table 4.2). All children tested had IQ scores in the normal range except for 1 
control sibling with significantly above average intellectual functioning with full scale IQ of 
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130. Specifically, no transplanted child had a full scale IQ less than 80. No differences 
were found in either transplanted patients or sibling controls compared to normative data 
in IQ, verbal comprehension, perceptual organisation, working memory, and processing 
speed. When academic function was tested with the WIAT-II Abbreviated, no differences 
in word reading, numerical operations and spelling between transplanted and control 
children were found (Table 4.2). Both groups, however, had significantly reduced 
numerical operation ability compared to normative data (p=0.001 for transplants, and 
p=0.01 for controls). 
Cognitive function was assessed via subtests of the WISC-IV (Table 4.3). There 
was little difference between transplanted patients and controls in all subtests.  No visual–
spatial difficulties were identified in transplanted patients. When compared to the normal 
population, however, siblings performed better than average in coding, a measure of 
speed of information processing; and in comprehension, which measures verbal reasoning 
and conceptualization, and social judgement and maturation.  
Memory and learning was assessed with WRAML-2 and RCF tests (Table 4.4). 
Transplanted patients had reduced scores in all subtests of Story Memory compared to 
controls, although further examination of data revealed that this was due to control patients 
performing significantly better than normal (p=0.001). No difference was found between 
transplanted patients and sibling controls on other WRAML-2 subsets of verbal learning, 
design or picture memory. On the RCFT, although no difference was noted between 
groups, both performed below population normal for Intermediate and Delayed Recall 
(p=0.03, and p=0.01 respectively for transplanted patients). 
Executive function was tested directly with the DKEFS, and indirectly with parents 
completing the BRIEF questionnaire (Table 4.5).  Transplanted patients had more rule 
violations in the tower test on the DKEFS, which indicates difficulties with self-regulation, 
and maintenance of cognitive and instructional set, compared to siblings and normative 
data. Interestingly, these difficulties were also noted on the parent-reported BRIEF where 
transplanted patients had more reported difficulties in initiation, planning and organisation, 
compared to their siblings. Sibling controls performed above age-appropriate expectations 
in switching and inhibition on the Colour-Word Interference subtest of the DKEFS. Visual 
scanning on the Trail Making subtest was also reduced in transplanted patients compared 
to siblings. 
On the Conners Rating Scale-Revised, transplanted patients scored higher than 
their siblings in Attention Deficit Hyperactivity Disorder (ADHD), inattention, and DSM-IV: 
Inattention indices (Table 4.6). While the mean ADHD Index score in transplanted patients 
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was less than 60, the conventional cut off associated with clinical significance, 4/13 (31%) 
transplanted patients scored above this, whereas no sibling scored in the clinically 
significant range. There were no significant differences in the other domains of emotional 
and behavioural function between transplanted patients, their siblings, and normative data. 
Aside from attention problems, there were no significant differences between transplanted 
children and their sibling controls on behavioural assessment on the CBCL (Table 4.6). 
However, when compared with normative data, transplanted children were significantly 
more anxious (p=0.02), withdrawn with depressive behaviour (p=0.01), had increased 
somatic complaints (p=0.004), social (p=0.03), thought (p=0.004) and attention (p=0.002) 
problems, increased rule breaking (p=0.03), and more aggressive behaviour (p=0.01). 
Siblings however also scored higher than normative data in all these domains resulting in 
little difference between the groups.  
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DISCUSSION 
These results show transplant recipients performing better than previously reported, with 
mean IQ scores in the normal range and similar to their siblings. While some difficulties 
with mathematics were noted in the transplanted children, this was similar to their siblings. 
Potential reasons for discrepancies in IQ scores between studies include variations in tests 
used, age at assessment, era of transplantation, time from transplant, ongoing chronic 
illness, malnutrition, and post transplant event free survival. A potential explanation for our 
cohort performing better than previously reported is the increased time since transplant. 
Unlike previous studies, which were often a mixture of short to long-term survivors, this 
sample was restricted to only long-term survivors with median follow up time of 10.89 
years after transplant, which is longer than previously reported. We also used the same 
tests in all patients, as they were all school aged, to avoid differences between 
assessment methods.  
We are not the only group to report normal mean IQ in transplanted patients. Two 
recent North American studies have reported their cohorts to have full scale IQ in the 
normal range (23, 24). Robertson et al from Edmonton, Canada, found mean full scale IQ 
of 93.9 in a study of 33 children, 89% of their transplant cohort, at kindergarten entry (23). 
The SPLIT consortium, reported mean full scale IQ 94.7 in a study of 144 children aged 5-
7 years, although only 32% of potentially eligible patients participated in this study (24). Of 
concern, 30% of their cohort had evidence of intellectual impairment, but interestingly, an 
earlier report by this group found the most important predictor of educational support after 
transplant was the requirement for educational support pre-transplant, Odds Ratio 22.5 
(25). They concluded that non-transplant factors were important in determining post 
transplant outcomes (25). While chronic illness in the pre-transplant phase may result in 
underachievement, inherent ability of the child or the family environment is also likely to be 
a significant contributor. The use of siblings as controls in our study therefore enabled us 
to exclude family factors such genetic potential and family environment on these children’s 
performances.  
It is likely however that with advances in the management of chronic liver disease 
and improved outcomes of liver transplant patients over time, using gross measures such 
as IQ assessment will be insufficient and more specific testing is necessary to adequately 
assess neurocognitive function. In recognition of this, we assessed our cohort for more 
subtle cognitive deficits including executive functioning. In contrast to previous studies, 
which were reliant on parent or teacher reports, we assessed executive functioning 
directly. Transplanted patients exhibited difficulties with goal setting, problem solving, self-
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regulation, and maintenance of cognitive set, with divided attention and impulsivity. While 
these difficulties generally did not translate to reduced academic function on assessment, 
these changes are likely to affect their function in adulthood. These findings suggest that 
transplanted patients may have difficulty multi-tasking and following instructions, which 
may then affect compliance with medical care and cause problems in the work 
environment. Visual scanning was also reduced in transplanted patients. Difficulties with 
visual scanning are associated with increased risk of accidents when controlling motor 
vehicles (26).  
Transplanted patients scored higher on the ADHD index on Conners testing than 
their siblings. Of relevance, 31% (4/13) of transplanted patients had clinically significant 
scores whereas none of the siblings did. While a gender effect was considered since all 
sibling controls were female, three of the four patients who scored in the clinical range 
were female. Interestingly, although transplanted patients were more anxious, had more 
somatic complaints and more thought problems than normal, they were not different to 
their siblings. This suggests that chronic illness in one member affects the whole family 
and it would be interesting to assess the psychosocial and mental health of parents as 
parental stress is recognised to affect the behaviour and psychosocial health of all 
children, including the physically healthy, in the family, as is seen in children with acquired 
brain injury (27).  
This study is limited by low patient numbers, despite recruiting 45% of potentially 
eligible patients in our centre, which may impact on interpretation of data. No differences, 
however, were noted between study subjects and non-participants, except for current 
calcineurin inhibitor therapy, but this is unlikely to be clinically significant. As such, the 
sample is thought to be relatively representative of long-term survivors of liver 
transplantation. The use of sibling controls, particularly the two sets of twins, adds weight 
to these findings. While the other limitation of our study was that all the control siblings 
were female and were not aged matched, the difficulties identified remained even when 
compared to the normal population, excluding a gender effect.  
  The findings of this study are important as it is the first study to directly assess the 
executive function of transplanted patients, rather than rely on parent or teacher reporting. 
It is also the only study to use siblings as controls to preclude the effect of genetic and 
family environment affecting outcomes. The twin pairs add weight to these findings despite 
our low numbers and lack of age matching for the rest of the cohort. We also report the 
longest follow up time with median 10.89 years post liver transplant for comprehensive 
neuropsychological testing. 
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These results are encouraging and better than previously reported with normal full 
scale IQ, cognition, and academic function in long-term survivors after liver transplantation. 
The emotional difficulties identified were also present in siblings suggesting environmental 
rather than biological illness effect. While these results suggest it may be possible for long-
term survivors of childhood liver transplant to achieve their underlying potential in gross 
testing such as IQ and academic function, ongoing difficulties in executive function and 
increased likelihood of ADHD will likely be relevant. Further studies examining these more 
subtle psychometric changes, particularly in executive function and behaviour are 
necessary. Collaborative multi-centre studies are likely to be necessary to generate 
appropriate patient numbers. Routine clinical assessment of cognitive functioning, 
including executive functioning, and behaviour post transplant is recommended. 
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Table 4.1: Demographics of eligible transplanted patients 
 
 Subjects  
(n=13) 
Others  
(n=16) 
p value 
Boys 46% (n=6) 44% (n=7) 1.00 
Median age at OLT (yrs) 1.15 (0.38-10.00) 0.86 (0.58-7.62) 0.83 
Mean PELD score 13.4 15.7 0.41 
Mean Height Z at OLT -1.20 ± 1.36 -1.29 ± 1.48 0.86 
Median time post OLT 
(yrs) 
10.89 (5.16-16.37) 11.08 (6.78-16.88)^ 0.86 
DIAGNOSIS    
Biliary Atresia 8 14 0.19 
Alagille 3 1  
A1AT 1 0  
PFIC 1 0  
Crigler-Najjer Syndrome 0 1  
TRANSPLANT ERA    
>2000 7.7% (n=1) 0  
1991-2000 84.6% (n=11) 88% (n=14) 1.00 
≤1990 7.7% (n=1) 12% (n=2)  
IMMUNOSUPPRESSION    
Tacrolimus 38% (n=5) 75% (n=12) 0.07 
Cyclosporine 54% (n=7) 25% (n=4) 0.14 
Other  8% (n=1) 0  
^ Time from transplant in non-participants was calculated to 25 Jan 2007; the median date 
when psychometric testing was undertaken in subjects.  
OLT: Orthotopic Liver Transplant; PELD: Pediatric End-stage Liver Disease; A1AT: Alpha-
1-antitrypsin deficiency; PFIC: Progressive Familial Intrahepatic Cholestasis 
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Table 4.2: Intellectual and academic function (WISC-IV and WIAT-II tests) 
 
Specific Tests Transplant  
(n=13) 
Controls 
(n=6) 
Diff. of 
means 
95% CI p 
value 
WISC-IV      
Full scale IQ 97.38±11.59 105.17±16.12 -7.79 -21.42 to 5.84 0.30 
Verbal 
comprehension 97.31±10.79 108.83±16.38 
 
-11.52 
 
-24.74 to 1.70 0.13 
Perceptual 
organisation 100.77±16.19 101.67± 21.29 
 
-0.90 
 
-19.48 to 17.68 0.93 
Working 
memory 97.08±9.38 99.67± 6.56 
 
-2.59 
 
-11.59 to 6.41 0.50 
Processing 
speed 95.92±11.32 104.00±10.51 
 
-8.08 
 
-19.63 to 3.47 0.15 
WIAT-II      
Word reading 96.00±14.79 99.50±15.24 -3.5 -19.04 to 12.04 0.64 
Numerical 
operations 86.15±12.92 92.33± 9.14 
 
-6.18 
 
-18.61 to 6.25 0.19 
Spelling 98.15±13.26 100±10.75 -1.85 -14.94 to 11.24 0.75 
Diff. of means: Difference of means; CI: Confidence Interval; WISC-IV: Wechsler 
Intelligence Scale for Children -Fourth Edition; WIAT-II: Wechsler Individual Achievement 
Test -Second Edition 
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Table 4.3: Cognitive Function (WISC-IV subtests) 
 
Specific Tests Transplant  
(n=13) 
Controls 
(n=6) 
Diff. of 
means 
95% CI p value 
Block design 9.38±2.47 10.33±4.46  -0.95 -4.27 to 2.37 0.93 
Similarities 9.23±2.59 12.17±3.37 -2.94 -5.9 to 0.02 0.34 
Digit Span 9.69±2.36 9.83±1.72 -0.14 -2.42 to 2.14 1.00 
Picture 
Concepts 9.92±3.35 10.00±2.61 
 
-0.08 
 
-3.36 to 3.2 0.93 
Coding 9.46±1.98 11.33±1.63 -1.87 -3.83 to 0.09 0.19 
Vocabulary 9.23±2.35 10.17±3.37 -0.94 -3.74 to 1.86 0.81 
Letter-Number 9.46±1.76 10.33±1.21 -0.87 -2.56 to 0.82 0.16 
Matrix 
Reasoning 11.00±3.34 10.50±4.37 
 
0.50 
 
-3.32 to 4.32 0.47 
Comprehension 10.31±1.75 12.33±2.34 -2.02 -4.04 to 0.00 0.03 
Symbol Search 9.15±2.44 10.83±1.83 -1.68 -4.05 to 0.69 0.46 
Diff. of means: Difference of means; CI: Confidence Interval; WISC-IV: Wechsler 
Intelligence Scale for Children -Fourth Edition 
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Table 4.4: Memory and Learning (WRAML2 and RCFT tests) 
 
Specific Tests Transplant  
(n=13) 
Controls 
(n=6) 
Diff. of 
means 
95% CI p value 
WRAML-2      
Verbal Learning: 
Immediate 
 
10.92±3.55 
 
9.67±3.88 
 
1.25 
 
-2.55 to 5.05 
 
0.37 
Delayed 10.38±3.36 10.00±3.29 0.38 -3.10 to 3.86 0.08 
Recognition 10.73±2.65 11.50±2.96 -0.77 -3.75 to 2.21 0.71 
Story Memory: 
Immediate 
 
10.85±2.82 
 
14.17±2.14 
 
-3.32 
 
-6.07 to -0.57 
 
0.05 
Delayed 10.85±2.54 14.00±1.41 -3.15 -5.51 to -0.79 0.02 
Recognition 10.92±2.43 13.50±1.22 -2.58 -4.82 to -0.35 0.17 
Design Memory: 
Immediate 
 
9.23 ±3.14 
 
9.83±1.72 
 
-0.60 
 
-3.51 to 2.31 
 
0.82 
Recognition 9.31±2.53 9.83±3.06 -0.52 -3.33 to 2.29 0.82 
Picture Memory: 
Immediate 
 
9.62±2.69 
 
11.00±1.26 
 
-1.38 
 
-3.84 to 1.08 
0.53 
Recognition 10.15±2.91 9.80±3.42 0.35 -3.05 to 3.75 0.69 
Finger Windows 8.92±2.47 9.67±3.27 -0.75 -3.59 to 2.09 0.94 
Number-Letter 10.081±2.93 10.17±1.72 -0.09 -2.83 to 2.65 0.57 
RCFT      
RCFT: Immediate 36.10±28.71 30.00±26.04 6.10 -23.48 to 35.68 0.50 
RCFT: Delayed 28.82±25.60 32.50±30.38 -3.68 -34.26 to 26.91 0.78 
RCFT: 
Recognition 
 
52.10±28.96 
 
54.20±40.19 
 
-2.10 
 
-39.77 to 35.57 
 
0.43 
Diff. of means: Difference of means; CI: Confidence Interval; WRAML-2: Wide Range 
Assessment of Memory and Learning –second edition; RCFT: Rey-Osterrieth Complex 
Figure Test 
 131 
Table 4.5: Executive Functioning (DKEFS and BRIEF) 
 
Specific Tests Transplant  
(n=13) 
Controls 
(n=6) 
Diff. of 
means 
95% CI p 
value 
DKEFS      
Visual Scanning 8.67±2.15 11.50±2.51 -2.83 -5.24 to -0.42 0.03 
Number Sequencing 8.08±4.12 10.67±1.97 -2.59 -6.39 to 1.21 0.43 
Letter Sequencing 8.42±2.27 11.00± 3.16 -2.58 -5.32 to 0.16 0.16 
Switching 8.00±4.09 12.00±2.00 -4.00 -7.78 to -0.22 0.09 
Motor 8.30±3.68 9.50±5.80 -1.2 -6.46 to 4.06 0.84 
Letter Fluency 9.08±3.12 11.83±3.19 -2.75 -6.08 to 0.58 0.30 
Category Fluency 12.45±3.47 12.50±2.74 -0.05  -3.56 to 3.46 0.87 
Category Switching 10.55± 3.30 12.00±3.94 -1.45 -5.49 to 2.59 0.40 
Switching Accuracy 11.55±3.14 11.80±2.77 -0.25 -3.77 to 3.26 0.61 
Colour Naming 10.75±2.30 11.67±2.07 -0.92 -3.28 to 1.44 0.07 
Word Naming 9.67±2.35 10.67±2.88 -1.00 -3.68 to 1.68 0.12 
Inhibition 9.75±2.05 13.33±1.97 -3.58 -5.73 to -1.44 0.04 
Inhibition/Switch 9.33±3.14 10.67±3.56 -1.34 -4.81 to 2.13 0.75 
Tower Test Total 11.25± 2.70 10.33±2.88 0.92 -2.01 to 3.84 0.78 
Tower Rule Violation 61.17±48.15 30.17±37.82 31.00 -16.85 to 78.88 0.28 
BRIEF      
Inhibit 51.46±11.76 46.17±8.54 5.29 -6.07 to 16.65 0.88 
Shift 49.46±11.09 51.50±12.97 -2.04 -14.20 to 10.12 0.95 
Emotional Control 48.31±10.62 46.00±7.87 2.31 -7.99 to 12.61 0.66 
Initiate 56.92±16.23 45.67±8.73 11.25 -3.78 to 26.28 0.30 
Working Memory 57.15±14.29 47.50±8.02 9.65 -3.65 to 22.95 0.39 
Planning/Organisatio
n 
57.62±11.82 44.33±10.27 13.29 1.43 to 25.15 0.13 
Organising Materials 50.46±11.68 43.67±9.83 6.79 -4.84 to 18.42 0.17 
Monitor 51.69±11.57 43.67±12.08 8.02 -4.19 to 20.23 0.23 
Behavioural 
Regulation Index 
46.00±15.88 47.33±0.03 -1.33 -16.33 to 13.67 0.74 
Metacognition Index 55.85±12.66 47.17±12.43 8.68 -4.43 to 21.79 0.35 
Global Executive 53.62±11.72 44.83±10.98 8.79 -3.19 to 20.77 0.30 
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Composite 
Diff. of means: Difference of means; CI: Confidence Interval; DKEFS: Delis-Kaplan 
Executive Function Test; BRIEF: Behaviour Rating Inventory of Executive Function 
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Table 4.6: Behaviour and Emotional Function (Conners Parent Rating Scale & CBCL) 
 
Specific Tests Transplant  
(n=13) 
Controls 
(n=6) 
Diff. of 
means 
95% CI p 
value 
Conners      
Oppositional  49.38±7.48 46.33±5.35 3.05 -4.16 to 10.25 0.45 
Cognitive 
Problems / 
Inattention 
56.31±14.17 47.83±7.76 8.48 -4.67 to 21.63 0.41 
Hyperactivity 51.08±11.05 50.67±8.43 0.41 -10.36 to 11.19 0.48 
Anxious / Shy 53.00±10.26 47.83±5.38 5.17 -4.31 to 14.64 0.26 
Perfectionism 49.77±7.33 48.67±5.82 1.10 -6.10 to 8.31 0.31 
Social Problems 53.62±13.26 53.00±12.39 0.62 -12.93 to 14.17 0.89 
Psychosomatic 51.08± 13.71 49.33±11.76 1.75 -11.96 to 15.46 0.72 
ADHD Index 55.31±14.01 45.67±5.99 9.64 -3.07 to 22.36 0.35 
Restless & 
Impulsive 
51.69±9.18 47.83±6.05 3.86 -4.87 to 12.58 0.90 
Emotional Lability 49.46±8.19 45.33±4.72 4.13 -3.52 to 11.77 0.09 
Index: Total 50.62±7.26 46.50±4.04 4.12 -2.63 to 10.87 0.34 
DSM-IV: 
Inattentive 
54.77±12.79 47.17±5.74 7.60 -4.05 to 19.25 0.37 
DSM-IV: 
Hyperactive-
Impulsive 
53.00±12.09 49.50±7.34 3.50 -7.86 to 14.86 0.93 
DSM-IV: Total 54.69±13.33 47.33±4.41 7.36 -4.57 to 19.28 0.48 
CBCL      
Anxious/ 
Depressed 
55.00±6.39 52.67±6.53 2.33 -4.37 to 9.03 0.42 
Withdrawn / 
Depressed 
56.54±8.25 54.5±6.98 2.04 -6.18 to 10.26 0.53 
Somatic Problems 58.54±8.85 55.00±10.35 3.54 -6.16 to 13.24 0.13 
Social Problems 55.00±7.16 55.67±12.91 -0.67 -10.28 to 8.94 0.89 
Thought Problems 57.92±7.88 56.50±9.29 1.42 -7.24 to 10.08 0.56 
Attention Problems 59.15±8.50 53.50±6.25 5.65 -2.58 to 13.88 0.49 
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Rule-breaking 
Behaviour 
53.92±5.65 53.33±8.16 0.59 -6.17 to 7.35 0.97 
Aggressive 
Behaviour 
55.31±5.23 52.83±6.01 2.48 -3.22 to 8.17 0.59 
Internalising 53.46±12.94 45.33±15.08 8.13 -6.04 to 22.30 0.09 
Externalising 51.38±8.98 45.50±12.55 5.88 -4.70 to 16.46 0.38 
Total 53.62±9.64 43.83±16.40 9.79 -2.74 to 22.32 0.20 
Diff. of means: Difference of means; CI: Confidence Interval; CBCL: Child Behaviour 
Check List; ADHD Index: Attention Deficit Hyperactivity Disorder Index; DSM-IV: 
Diagnostic and Statistical Manual of Mental Disorders- 4th edition. 
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DISCUSSION 
The findings from this body of work are highly encouraging as survivors of childhood liver 
transplantation can expect to attain normal height, weight, bone density, and IQ at long-
term follow up. This is very gratifying for the transplant community as it vindicates the role 
of transplantation and indicates an excellent outcome after a debilitating and life-
threatening illness. Our cohort achieved better outcomes than previously reported in many 
areas including growth and final height attained, BMD, IQ and cognition. The main 
differences between our cohort and previously reported studies to explain these improved 
results were duration of follow up, and degree of malnutrition. Depending on the outcome 
assessed, median follow up in our cohort was between 7 to 10 years post-transplant, with 
some patients >20 years post-transplant. Additionally, we excluded patients within 3-5 
years of transplant to avoid the effect of ongoing medical problems, unlike many previous 
reports with shorter duration of review and included recently transplanted patients. Our 
cohort was also not as malnourished or growth impaired before transplant, with mean pre-
transplant Z-scores for height and weight between -1.26 to -0.86, which is better than 
reported for many studies with less favourable outcomes. 
 Several limitations are acknowledged with our studies. While growth and body 
composition data was longitudinal, BMD and cognitive outcomes data described cross-
sectional outcomes. Longitudinal cognitive changes after transplant however are often 
fraught methodologically because of the necessity of using age appropriate instruments, 
which changes over time. The validity of comparing outcomes using different tests is 
problematic. We therefore deliberately restricted the study to school aged children, but 
additionally compared their performance to both the population normal and to their 
siblings, which we felt was more meaningful as it allowed for genetic and familial 
influences. Relatively low patient numbers in parts of these studies is another limitation but 
these numbers are comparable or better than most other single centre reports. Despite the 
low numbers, these studies describe relatively high proportion of overall cohort recruitment 
even when compared to large multicentre studies. Our studies also recruited and included 
patients throughout the lifetime of the transplant service and found that transplant era did 
not affect our outcomes. The main limitation of this thesis however has been the difficulty 
in identifying the effect of post transplant complications. Graft function and steroid use are 
likely to be the most important factors although the latter is often used as an indicator of 
the former. Interestingly, in our studies, post transplant management and complications 
were only important in long-term growth. This is probably because we restricted 
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recruitment to only those who were >3-5years after transplant when they are less likely to 
have ongoing medical and surgical complications.   
The persistent deficits found in our patients of reduced BCM and subtle cognitive 
and behavioural problems, would likely be considered acceptable and minor after a major 
life-threatening illness. These outcomes however, have potential to affect long-term quality 
of life and the ability of these survivors to have a “normal” productive adulthood. The lack 
of recovery of BCM many years after transplant was surprising since these survivors 
normalized their height, weight and BMI, reaching near the 50th centile. The inference of 
reduced BCM however, is that weight recovery in these survivors is due to increased fat 
mass, even though these patients were not overweight on BMI or weight Z-scores, or by 
subjective global assessment. The implication of increased fat mass is the risk of 
developing sarcopenic obesity, diabetes, and metabolic syndrome as they age. The 
reason for this lack of BCM recovery is unclear but steroids and other medications, 
underlying diagnosis, and pre-transplant malnutrition may all have a role in its 
development. On multiple regression analyses, only older age at transplant predicted 
lower BCM although the greatest reduction in BCM occurred in the most growth impaired 
children. Children with the lowest BCM therefore will have the highest risk of developing 
sarcopenic obesity.  
In adults, the post-transplant development of overweight and obesity has been 
attributed to a combination of improved liver function, resolution of anorexia, sedentary life-
style, and medication, particularly steroid use118. The role of immunosuppression in the 
development of obesity was proposed in an editorial in 2008 discussing whether children 
after liver transplant were more prone to non-alcoholic fatty liver disease119. Several 
studies have implicated steroids as the cause for reduced body cell mass and increased 
fat mass after renal transplantation66, 67. The use of steroids immediately post-transplant is 
almost universal for all solid organs and by all centres. Steroid dosing, duration of therapy, 
and weaning off thereafter varies between centres and organs being treated. 
Glucocorticoids are recognised to be important in programming the hypothalamic-pituitary 
axis and it is possible that exposure to high doses in the early post-transplant period is 
important120. Calcineurin inhibitors are also used universally for immunosuppression and 
while dosing may vary between centres, are often used as monotherapy to maintain long-
term immunosuppression. Calcineurin inhibitors have been reported to cause impaired 
muscle response to anabolic stimuli121. In our cohort however, we did not find steroid 
exposure viz. cumulative steroid dose in first 12 months, duration of use, and ongoing use, 
to be significant in predicting reduced BCM. This suggests variables other than steroids 
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are implicated in long-term reduction in BCM. We were unable to determine the effect of 
calcineurin inhibitor therapy on BCM since all our patients were on it after transplant. 
Pre-transplant malnutrition, which is common in solid organ failure, is potentially 
another cause for post-transplant reduced BCM and increased fat. Obesity at long-term 
follow-up, after early life malnutrition or under-nutrition has been described in other 
conditions without steroid or calcineurin inhibitor use. Longitudinal studies of children born 
small for gestational age have reported increased adiposity in adulthood compared to 
those born appropriate weight for age122. Similarly, stunted children from slum areas, and 
those who survived famine in infancy have also been reported to be more likely to be 
obese in adolescence and adulthood123, 124. The co-existence of both childhood 
malnutrition and obesity in adolescence or adulthood is increasingly recognised in many 
developing societies and probably derived from the same physiologic responses124. These 
responses are consistent with developmental origins of health and disease (DOHaD) 
hypotheses where early life insults, either prenatally or the early post-natal period, result in 
metabolic re-programming with resultant effect in later life or adulthood125. These 
hypotheses are a development of Barker’s initial “thrifty phenotype” hypothesis, which 
proposed that intrauterine or infantile under-nutrition permanently affects metabolic 
responses, predisposing subjects to subsequent hypertension, diabetes and obesity in 
adulthood28. Singhal and Lucas later proposed that accelerated post-natal catch up growth 
was more important than the initial period of under-nutrition, and developed the concept of 
metabolic programming126. These ideas were then expanded to the “predictive-adaptive” 
hypothesis by Gluckman and Hanson, who suggested that an animal, after adapting to its 
early life environment, will continue to behave in this adapted way despite later 
improvement in nutritional environment127. These concepts of developmental plasticity, 
where programming of long-term metabolic responses may result from events/insults 
occurring in early childhood are thought to be effected by epigenetic mechanisms, where 
minor changes to chromatin structure without altering DNA sequencing result in heritable 
changes to gene expression128, 129. These nutritional epigenetic mechanisms at the cellular 
level include DNA methylation, histone modification, and non-coding microRNA30. 
The DOHaD hypotheses are an attractive explanation to account for increased fat 
noted after childhood organ transplantation; and there is some evidence of this in our 
cohort. The largest reduction in BCM was noted in children who were growth impaired at 
transplant, even though correction for height was made when calculating BCM.  Although 
these children had the best height recovery, they remained shorter and never caught up to 
those who were not growth impaired at transplant. Longitudinal height data from this study 
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suggested that poor post-transplant growth recovery was due to either the long-term 
consequence of chronic malnutrition, or a result of post-transplant care, such as steroid 
use. Similar findings of sub-optimal height recovery have been noted in other reports of 
post-transplant growth, but also after malnutrition. Growth impairment or stunting is 
considered to be a good marker of chronic malnutrition130. It is therefore feasible that the 
most malnourished have the least recovery in BCM post-transplant, and will be most at 
risk of developing obesity in adulthood. This is consistent with the DOHaD hypotheses, 
and explains the co-existence of childhood malnutrition and adult obesity seen in 
developing nations.  
The DOHaD hypotheses however, do not explain similar findings of increased 
obesity and sarcopenia also found after transplantation in adulthood since most adults 
have conditions which developed after childhood. DOHaD hypotheses are also 
inconsistent with our findings that increased age at transplant was predictive of reduced 
BCM at long-term follow up. Malnutrition however, is common to both adults and children 
with end-stage liver disease and other organ failure. Nutritional modifications are 
recognised to effect epigenetic mechanisms in adults, although most of the interest is in 
relation to ageing and cancer prevention. Dietary recommendations such as drinking green 
tea or eating turmeric arise from studies showing that green tea polyphenols affect DNA 
methylation, while curcumin from turmeric affects histone modification, resulting in anti-
cancer effects 128. It is thus conceivable that malnutrition per se, is the cause of the 
metabolic re-programming through epigenetic mechanisms; and its effects not age 
dependent, although there may be periods of increased susceptibility. Plasticity of 
metabolism may be retained throughout life with heightened responses during periods of 
rapid growth such as in infancy or the peri-natal period.  
Malnutrition in childhood is recognised to affect cognition in later life despite 
resolution of initial nutritional deficits55. Difficulties with school and academic attainment 
during adolescence, and attention deficits and hyperactivity in adults have been reported 
in those who were malnourished in early childhood97, 131. Other reported problems include 
deficits in analytic and reasoning skills, language, visual-spatial functions, working memory 
and even IQ; with the severity and duration of malnutrition being significant although 
deficits have been reported even in those with mild insults over an extended period55. Our 
cohort was found to have normal IQ, with no patients scoring low enough to be considered 
intellectually impaired. Mathematical and emotional difficulties noted in transplanted 
children were also noted in their siblings. Difficulties however, were noted with executive 
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functioning, self-regulation, visual scanning, and inattention when compared to their 
siblings and to the normal population.  
The neurocognitive findings of this study were better than expected compared to 
previous reports. Our small cohort achieved normal intellect with mean full scale IQ 97, 
almost at population mean of 100, in contrast to previous reports of low average 
intelligence, with intellectual impairment in 30-54% of patients104, 105. Era of transplantation 
was unlikely to account for this since 85% of our patients were transplanted between 1991 
to end of 2000. The main differences between our cohort and those reported from the 
large SPLIT studies were longer duration of follow up in our patients, mean 10.9 years vs. 
5.4 years post-transplant; and less growth impairment at transplant, height Z-score -1.2 vs. 
-1.7105. Chronic Iiver disease, hepatic encephalopathy, hypotension and cerebral 
ischaemia, as well as frequency and duration of general anaesthesia are some of the peri-
transplant factors that may potentially impact neurocognitive development of liver 
transplant survivors. It would however be difficult to elucidate which of these factors is the 
most important as many of these occur concurrently in transplant survivors.  
The strongest predictor for post-transplant special educational assistance in the 
SPLIT studies however, was the requirement for it pre-transplant, odds ratio 22.5, 
indicating that pre-transplant factors such genetic potential, family environment, 
malnutrition and underlying disease were more significant than transplantation and 
immunosuppression on long-term cognition110. Our study controlled for some of these pre-
transplant factors including genetic potential and environmental influences because we 
compared patients to their siblings, as well as to the normal population. Growth deficit at 
transplant, and requirement for tube feeding pre-transplant were also significantly 
correlated with need for special education on univariate analyses of SPLIT data, implying 
the effects of malnutrition110. The improved nutritional state of our cohort therefore may be 
the reason for improved cognitive outcomes compared to previous studies. While the 
effect of underlying liver disease and post-transplant care may impact on 
neurodevelopment, malnutrition alone is recognised to cause the difficulties described in 
our cohort, and therefore is likely significant in its development post-transplant. The subtle 
difficulties identified in transplanted children, even though seemingly minor, have potential 
to affect long-term QOL and function. Difficulty with executive functioning translates to 
problems with planning and organising, multi-tasking, and self-regulation. Disorganisation, 
inability to plan or self-regulate, and problems with multi-tasking all impact on compliance, 
ability to achieve academically, and performance in many occupations. Deficits in attention 
and concentration, also more common in transplanted children, will compound these 
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difficulties. Visual scanning is important for safe operation of a motor vehicle and problems 
in this area will increased the likelihood of vehicular accidents.  While these relatively 
subtle deficits may be within variance of a normal population, these findings were not 
found in their siblings. Early identification of these deficits enables implementation of 
coping strategies such as cognitive behaviour therapy, use of modern technology such as 
organisers or blind spot indictors, and even psychotropic medication use during schooling 
to ensure these children achieve to the best of their ability. Prevention or attenuation of 
these by improving pre-transplant nutritional state however is likely to be even more 
successful in ensuring normal long-term cognition.  
Malnutrition is recognised to cause bone disease including rickets, osteopenia, 
osteoporosis, and pathological fractures. Bone density assessment has been used to 
predict the propensity for osteoporosis and fractures. Pathological fractures after liver 
transplantation remains problematic in adult patients and BMD assessment has been 
recommended132. Unlike in adults, the utility of BMD in predicting fractures in children 
however is not defined as low bone mass alone is not a strong predictor of fracture in 
children133. The developmental difference in bone accretion or bone loss between children 
and adults is likely to be a reason for this difference although patient size is also significant 
since DXA measurements are influenced by this. In adults after transplant, the normally 
gradual reduction in BMD with aging is hastened by chronic illness, malnutrition and 
medication. In contrast, childhood coincides with a period of bone accretion to reach peak 
bone density at the end of adolescence. Children who are transplanted before they reach 
school age will likely benefit the most since they have resolution of malabsorption, 
malnutrition, and liver dysfunction prior to the period of maximal bone accretion.  
The timing of pathologic post-transplant fractures and long-term persistence of 
reduced BMD in our cohort is interesting. Pathologic fractures as a result of minimal or no 
trauma only occurred in two patients (5%, 2/42) within 18 months of transplant with no 
further fractures at long-term follow up to 10 years despite persistence of reduced BMD. In 
contrast, fractures from major trauma in children with normal BMD occurred years later, 
resulting in an overall post-transplant fracture rate of 12% (5/42) in our patients. None of 
the patients with traumatic fractures were on steroids at the time of fracture or DXA 
assessment. The two patients with pathologic post-transplant fractures also sustained 
fractures prior to transplant. One of these patients was severely malnourished with height 
Z-score -2.04 and on long-term steroids pre-transplant; while the other has cystic fibrosis, 
which is known to be associated with reduced BMD and increased fracture risk from a 
combination of genetic predisposition and malnutrition133.  Steroid use was not the main 
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reason for pathologic post-transplant fractures in our cohort, even though it was 
associated with long-term reduced BMD. Other factors, such as malnutrition, underlying 
disease, or primary bone disease, pose greater risks for development of post-transplant 
pathological fractures in children than steroids. Steroids are also not the cause of fractures 
after liver transplant in adults, with pre-existent osteopenia being the most important factor 
in predicting post-transplant bone disease in adults132. Improved pre-transplant nutrition, 
as evidenced by increased BMI and reduced muscle wasting, is thought to account for the 
improved pre-transplant BMD and reduced fracture incidence over time in adult liver 
transplant patients87.  
In our study, children with reduced BMD including the two with pathologic fractures 
were older at transplant, median 7.3 years, compared to those with normal BMD, median 
2.1 years, but this was not statistically significant. The lack of significance of age at 
transplant in our cohort may be because of the age groups we selected, which were based 
on previous reports; or our sample size. Maximal bone accretion occurs during puberty 
and adolescence so malnutrition and transplantation during this period can be expected to 
have the largest impact on subsequent bone density. Classifying children based on 
pubertal status would probably give a better indication about the effect of age at transplant 
but would be difficult to do as it involves clinical and possibly hormonal (with blood tests) 
staging of pubertal status. Children with reduced BMD tended to be shorter and lighter at 
follow up even though no difference was noted at the time of transplant.  While smaller 
children tend to have lower BMD on DXA compared to larger sized age matched peers, 
BCM which corrected for height was also reduced implying poorer recovery from 
malnutrition in those with reduced BMD. It would therefore seem likely that persistence of 
malnutrition predispose these children to long-term reduced BMD.  
The long-term consequences of any chronic illness are often attributed to the 
underlying disease process, the necessary treatment which in this case is liver 
transplantation, and ongoing medication use and its complications, or a combination of all 
these factors. The role of malnutrition on long-term outcomes after liver transplantation has 
not been recognised because it is thought to resolve rapidly after transplantation. A recent 
editorial discussing optimizing outcomes after liver transplantation in paediatric recipients 
identified complications associated with immunosuppression, risks for growth and 
intellectual impairment, barriers to compliance, and quality of life, but made no mention of 
the potential for malnutrition to affect all these areas134. Our results however show that 
pre-transplant malnutrition was the common factor in predicting many undesirable long-
term outcomes after liver transplantation including growth, body composition, and 
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cognition, while persistent post-transplant malnutrition may affect BMD and risk of 
fractures. Underlying disease is unlikely to be the cause since these outcomes are seen in 
both adults and children after transplantation, even though they have very different 
aetiologies of liver disease, although most had end-stage liver disease with associated 
malnutrition. 
These findings emphasize the importance of correcting pre-transplant malnutrition 
to improve outcomes both in the short and long term. Aggressive nutritional rehabilitation 
before transplantation, in addition to reducing peri-transplant complications, will result in 
improved growth, cognition, bone density both pre-transplant and at long-term follow up. 
This however may be at the expense of increased propensity to obesity in adulthood, 
although this may not eventuate if severe malnutrition is averted since both severity and 
chronicity of under-nutrition, and rate of improvement from it are thought to be important 
factors in metabolic programming according to the DOHaD hypotheses. The specific 
nutritional factors affecting this programming however remain undefined. We postulate 
however that plasticity of nutritional epigenetics is maintained throughout life since adult 
transplant survivors also manifest some of these long-term changes after malnutrition 
including reduced BCM and increased obesity. While there may be times of increased 
susceptibility, probably coinciding with periods of rapid growth such as intrauterine or early 
infancy, these epigenetic mechanisms will operate throughout life, especially if the stressor 
is significant, such as with organ failure or severe malnutrition. 
The possibility of manipulating or reversing these epigenetic changes needs further 
investigation. Animal models have demonstrated reversal of epigenetic changes with 
nutritional manipulation135. Exercise is also recognised to cause changes in DNA 
methylation136. Observational and interventional studies of dietary manipulation in adults 
suggest that plasticity of epigenetic mechanisms is retained even in adulthood137. The 
possibility of altering body metabolism through a combination of dietary manipulation and 
exercise is an attractive and topical concept. The field of nutritional epigenetics is evolving 
with much interest particularly in aging and anti-cancer effects, and the role of dietary 
personalization to optimize outcomes fascinating138. Further studies on how to effect 
changes in lean mass and BCM through nutritional manipulation and exercise are 
necessary as it would allow transplant recipients to optimize their outcomes. It would be 
interesting to see if the long-term BCM changes described in our cohort also occur in 
adults after liver transplantation and in children after other solid organ transplantation. The 
effect of dietary manipulation such as increasing protein intake, or using branched-chain 
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amino acids, as well as the role of exercise on BCM and also BMD also warrant further 
investigation.     
This study has demonstrated that many long-term outcomes after childhood liver 
transplantation, often attributed to factors such steroid use, were significantly affected by 
pre-transplant malnutrition; and aggressively treating this will optimize both short and long-
term outcomes. Nutritional compromise however, persists even at long-term review, with 
reduced BCM and increased propensity for sarcopenic obesity noted in transplant 
survivors. More research on nutritional rehabilitation to reduce pre-transplant malnutrition, 
and post-transplant dietary and exercise manipulation to effect epigenetic changes are 
necessary to further improve outcomes for children after liver transplantation.  
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CONCLUSIONS 
Survivors of childhood liver transplantation can expect to achieve normal height, weight, 
BMD, and IQ at long-term follow up.  
 
Growth recovery continues for at least 10-15 years post-transplant. Growth impaired and 
malnourished children at transplant, even though they had the best recovery, remained 
shorter and lighter than their peers with post-transplant management, likely steroid use, 
impacting on long-term growth. 
 
BCM remains reduced at long-term follow up implying that weight recovery is due to 
increased fat mass. Growth impaired children had the largest reduction in post-transplant 
BCM, suggesting persistence of malnutrition. 
 
Pathologic post-transplant fractures occur within 18 months of transplant and are not 
predicted by steroid use. Reduced BMD at long-term follow up is associated with ongoing 
steroid use.  
 
Transplant recipients achieved normal intellect and cognition, but exhibit difficulties with 
executive functioning and have attention deficits. 
 
Most of these adverse outcomes can be attributed to malnutrition alone, and improving 
pre-transplant nutrition will likely improve these long-term outcomes.  
 
Transplant recipients remain at risk of sarcopenic obesity and subsequent metabolic 
syndrome.  
 
Nutritional compromise persists in long-term survivors of childhood liver transplantation.  
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